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ABSTRACT 
 
Focusing on the molecular mechanisms of normal and abnormal thyroid development, this 
work had two main aims: 
1) To establish a flow cytometry protocol for the developing and adult murine thyroid. 
2) To analyze whether epigenetic mechanisms are regulating thyroid development. 
 
Project 1: A new tool for thyroid research: Flow cytometry of the thyroid gland 
The thyroid is composed of endocrine epithelial cells, blood vessels and mesenchyme. 
However, no data exist so far on absolute cell numbers, relative distribution, and proliferation 
of the different cell populations of the thyroid. First, we established a gating strategy for flow 
cytometry that is able to identify seven distinct cell populations in the embryonic and adult 
thyroid. Second, a detailed analysis of cell populations in vivo revealed unexpected 
frequencies and cell growth dynamics of the different cell populations at distinct embryonic 
stages and in adult tissues, extending our current knowledge on normal thyroid development. 
Finally, a yet unknown and uncharacterized cell population present in embryonic and adult 
thyroids at a frequency between 5-20% has been identified, that needs further detailed 
characterization. In summary, our approach provides a useful new tool for cell function 
analyses in murine thyroid disease models. 
 
Project 2: A new concept: Epigenetic regulation of thyroid development 
Abnormal thyroid development results in thyroid dysgenesis (TD). TD causes congenital 
hypothyroidism in neonates. Monozygotic twin are discordant for TD, suggesting epigenetic 
mechanisms. This epigenetic concept is further supported by disrupted histone acetylation in 
thyroid cancer and pathologic development of organs after inhibition of histone deacetylases 
(HDAC). To investigate the role of HDACs for normal and abnormal thyroid development, 
we first documented physiological dynamic changes of HDAC activity, HDAC expression 
and histone acetylation in the thyroid between E13.5-E17.5 in vivo. Second, we investigated 
the effect of HDAC inhibition on thyroid development in an ex vivo embryonic thyroid 
culture model. HDAC inhibition induced decreased HDAC activity and increased histone 
acetylation. HDAC inhibition resulted in profoundly disordered thyroid development 
compatible with all aspects of TD: reduced follicle formation, decreased endocrine cell mass, 
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and disturbed angiogenesis. Hence, our data supports the concept of epigenetic regulation of 
thyroid development, and suggests a new molecular mechanism of TD.   
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1. INTRODUCTION  
 
 
The thyroid gland is the first endocrine gland to develop in the embryo and is responsible for 
the synthesis and secretion of thyroid hormones. Thyroid hormones act on virtually every cell 
in the body to affect body growth, metabolic rate and development, and under or over 
production of these hormones have potent effects. Since thyroid hormones are essential for 
physical and mental development, hypothyroidism in utero and postnatally might cause 
mental impairment and reduced physical growth (Braverman and Cooper, 2012).  
 
The anatomy and physiology of thyroid gland is very well studied. However, the relative 
distribution of all the major cell types in embryonic and adult thyroid as well as the growth 
dynamics during embryonic development is not well characterized. One previous study in the 
adult dog thyroid had quantified the different cell populations by transmission electron 
microscopy. They showed 70% of thyroid cells were epithelial cells, 6% endothelial cells, and 
24% fibroblasts. However, these results were never confirmed in other species (Dow et al., 
1986). Another study in adult rat thyroids had quantified TFCs in vivo by flow cytometry 
observed 40% TG-positive TFCs, and 2-4% calcitonin-positive C-cells (Moerch et al., 2007). 
However, the remaining cell types were not characterized and quantified.  
 
CH is the most frequent endocrine disease in infants, with an incidence of about 1:3000 to 
1:4000 newborns (Rastogi and La Franchi, 2010).  The most common cause of CH in the 
developed world is defects in the various important steps of thyroid development that result in 
thyroid dysgenesis (TD). TD is characterized by a spectrum of developmental defects of the 
thyroid ranging from complete absence of thyroid gland (athyreosis), abnormally located 
thyroid gland (ectopic), a normally located but smaller in size thyroid (hypoplastic) or 
orthotopic thyroid of normal size without function.  
 
TD is believed to be a sporadic disease (98% of cases are non-familial). Also, human genetic 
studies suggest that TD has a discordance rate of 92% in monozygotic twins (Perry et al., 
2002). Mutations in transcription factors that are expressed in developing and in functioning 
adult thyroid gland have been implicated as a cause of TD, however these are found in only 
2% of the cases. An exact cause in the remaining of the cases still remains unknown. Recent 
findings suggest that genetics of TD mostly do not follow Mendelian patterns and alternative 
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mechanisms such as multigenic defects and epigenetic processes need to be considered 
(Vassart and Dumont, 2005; Szinnai, 2014a). In thyroid cancer cells, changes in gene 
expression due to epigenetic mechanisms involving aberrant modifications by histone 
acetylation or methylation have been shown (Kondo et al., 2008; Russo et al., 2011). There is 
increasing evidence of epigenetic mechanisms, especially histone modifications being critical 
during murine embryonic development of pancreas (Haumaitre et al., 2008), intestine (Tou et 
al., 2004) and kidney (Chen et al., 2011).  
 
Two main important questions are addressed in this thesis:  
1. Development of a new tool for thyroid research by using flow cytometry for 
characterization and growth dynamics of mouse thyroid gland during embryonic development 
and in adult stage. 
2. Analyze the role of HDACs and histone acetylation for the regulation of thyroid 
development.  
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1.1 Thyroid gland   
1.1.1 Anatomy and histology 
Thyroid gland is a butterfly-shaped endocrine organ located in the anterior neck, on the 
trachea and inferior to the larynx. Two lateral thyroid lobes are connected by median isthmus. 
The main function of the thyroid gland is to store iodide and make it available for the 
synthesis of thyroid hormones. Each lobe is composed of two distinct endocrine cell types - 
the Thyroid follicular cells (TFCs) and the Parafollicular cells or C-cells.  
TFCs are organized into thyroid follicles, the structural and functional unit of the gland 
(Figure 1). Thyroid follicles are made up of monolayer of TFCs enclosing the follicular 
lumen, which is filled with colloid. Colloid contains iodothyroglobulin, a precursor of thyroid 
hormones (Tortora and Derrickson, 2008; Polak and Szinnai, 2013). Thyroid hormones are 
synthesized and stored in the follicles. Follicles vary in size, depending upon the degree of 
distention, and are surrounded by dense network of capillaries, lymphatic vessels, sympathetic 
nerves and angiofollicular unit. The TFCs produce thyroid hormones Tetraiodothyronine or 
“T4” and Triiodothyronine or “T3” (Tortora and Derrickson, 2008; Polak and Szinnai, 2013). 
C-cells or parafollicular cells constitute 2-4% of all cells in an adult thyroid and are located 
adjacent to the follicles and produce the hormone calcitonin that helps in maintaining calcium 
homeostasis. The four parathyroid glands are an independent endocrine organ located near the 
posterior aspect of the thyroid gland. These glands produce parathyroid hormone (PTH), 
which has effects antagonistic to those of calcitonin and helps in maintaining calcium and 
phosphate homeostasis (Tortora and Derrickson, 2008). 
The anatomy and physiology of thyroid gland is very well studied. However, the relative 
distribution of all the major cell types in embryonic and adult thyroid as well as the growth 
dynamics during embryonic development is not well characterized. One of the oldest studies 
in the adult dog thyroid had quantified the different cell populations by transmission electron 
microscopy. They showed that 70% of the thyroid cells were epithelial cells, 6% endothelial 
cells, and 24% were fibroblasts. However, these results were never confirmed in other species 
(Dow et al., 1986). Another study in adult rat thyroids had quantified TFCs in vivo by flow 
cytometry observed 40% TG-positive TFCs, and 2-4% calcitonin-positive C-cells (Moerch et 
al., 2007). However, the remaining cell types were not characterized and quantified. 
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1.1.2 Thyroid hormone synthesis 
The synthesis of thyroid hormones takes place in the thyroid follicles and requires a normally 
developed thyroid gland, an adequate nutritional intake of iodide, and a series of sequential 
biochemical steps. The TFCs synthesize and secrete hormones T3 and T4 as follows: 
Iodide trapping  
Active transport of iodide into the thyroid gland is a crucial and rate-limiting step in the 
biosynthesis of thyroid hormones (Dai et al., 1996; Szinnai et al., 2007; Spitzweg and Morris, 
2010; Portulano et al., 2014). TFCs trap iodide ions (I-) by actively transporting them from 
the blood into the cytosol. As a result, the thyroid gland normally contains most of the iodide 
in the body. Sodium iodide symporter (NIS) is the protein responsible for iodide uptake at the 
basolateral membrane and is encoded by the SLC5A5 gene. NIS co-transports two sodium 
ions along with one iodide ion, with the transmembrane sodium gradient serving as the 
driving force for iodide uptake. This sodium gradient that provides the energy for this transfer 
is generated by Na+/K+-ATPase. Following the active transport, iodide is translocated across 
the apical membrane by passive or facilitated transport into the follicular lumen by 
Figure 1. Adult thyroid gland of the mouse. Hematoxylin and Eosin staining of an adult mouse thyroid gland. 
1) thyroid follicle, 2) monolayer TFC epithelium, 3) follicular lumen filled with colloid, 4) C-cells, 5) 
parathyroid gland. 
Sanjay Gawade, Unpublished data. 
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chloride/iodide transporter pendrin (SLC26A4/ PDS) (Royaux et al., 2000; Bizhanova and 
Kopp, 2009; Pesce et al., 2011; Darrouzet et al., 2014).  
Synthesis of thyroglobulin  
TFCs synthesize thyroglobulin (TG), a large glycoprotein that is produced in the rough 
endoplasmic reticulum, modified in the Golgi complex, and packaged into secretory vesicles. 
The vesicles then undergo exocytosis, which releases TG into the lumen of the follicle. TG 
serves as matrix for TH synthesis and storage (Lee et al., 2009; Tortora and Derrickson, 2008; 
Polak and Szinnai, 2013).  
 
  
 
	
	
	
	
	
	
	
	
	
 
	
 
	
	
Figure 2: Main steps involved in the thyroid hormone synthesis. At the basolateral membrane, iodide is 
transported into thyrocytes by the sodium iodide symporter (NIS). At the apical membrane, iodide efflux is 
mediated by pendrin (PDS). Iodide is oxidized by TPO in the presence of H2O2. Thyroglobulin (TG) secreted 
into the follicular lumen serves as matrix for synthesis of T3 and T4. First, TPO catalyzes iodination of selected 
tyrosyl residues (organification) to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). Subsequently, TPO 
catalyzes the coupling of two iodotyrosines to form either T4 or T3. Iodinated TG is stored as colloid in the 
follicular lumen until needed. For the release of thyroid hormones, TG is internalized into the follicular cell by 
pinocytosis and digested in lysosomes. These processes generate T4 and T3 that are released into the bloodstream 
through unknown mechanisms. The unused MIT and DIT are retained in the cell and deiodinated by the 
dehalogenase 1 (DEHAL1). The released iodide is recycled for thyroid hormone synthesis.  
Taken from Bizhanova and Kopp, 2009. 
 
 
14 
Oxidation of iodide and iodination of tyrosine  
Iodide ions undergo oxidation to form iodine that binds to tyrosine in TG. Thyroid (TPO) 
catalyzes two key steps of thyroid hormone synthesis, namely organification and coupling 
(Figure 2). Organification of iodide to bind iodine to tyrosyl residues in TG needs the 
presence of hydrogen peroxide (H2O2), resulting in the production of monoiodotyrosine 
(MIT) and diiodotyrosine (DIT). Then, coupling of one MIT and one DIT or two DIT 
residues takes place, resulting in iodinated TG molecules forming T3 or T4 respectively. 
H2O2 is generated by two nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 
called dual oxidases 1 and 2 (DUOX1 and DUOX2). Generation of H2O2 as well as binding 
of oxidized iodide to tyrosine residues of TG and formation of THs are activated by the TSH-
dependent phospholipase C-Ca2+ pathway and inhibited by cyclic adenosine monophosphate 
(cAMP) signaling cascades (Stathatos, 2006; Song et al., 2007; Grasberger, 2010). 
Thyroglobulin pinocytosis and secretion of thyroid hormones 
For the release of thyroid hormones, iodinated TG molecules are reabsorbed into the follicular 
cells by pinocytosis. These molecules undergo lysosomal digestion that release T4 and T3 
into the bloodstream via the basolateral membrane through an unknown mechanism. The 
unused MIT and DIT undergoes deiodination that is mediated by iodotyrosine dehalogenase 1 
(DEHAL1), representing an important mechanism of iodine recycling within the TFCs for 
future TH synthesis (Figure 2) (Bizhanova and Kopp, 2009; Kleinau et al., 2013; Iglesias et 
al., 2014). 
Control of thyroid hormone synthesis 
Iodine availability and thyroid-stimulating hormone (TSH) are the two most important factors 
controlling thyroid hormone synthesis. Deficient amounts of iodine leads to decreased thyroid 
hormone production, increased secretion of TSH, and in an attempt to compensate may also 
cause goiter. In contrast, higher concentration of iodide acutely inhibits thyroid hormone 
synthesis by inhibiting the generation of H2O2 (the Wolff-Chaikoff effect) (Wolff and 
Chaikoff, 1948) and thus blocking TG iodination (Dunn and Dunn, 2001).  
The plasma levels of THs are under the regulation of the hypothalamic-pituitary-thyroid 
(HPT) axis. When the serum levels of T4 and T3 are low, TSH is released from the anterior 
pituitary gland. TSH is considered to be the key regulatory factor controlling the synthesis 
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and secretion of THs. Thyrotropin-releasing hormone (TRH) secreted from the hypothalamus 
controls the release of TSH. (Costa-e-Sousa and Hollenberg, 2012). TSH binding to TSHR 
leads to the activation of the enzyme adenylate cyclase (AC). The consequent increase in 
cAMP intracellular levels together with the activation of cAMP-dependent protein kinase A 
(PKA) mediate the TSH-dependent synthesis of THs (Yen, 2001; Rivas and Santisteban, 
2003; Kleinau et al., 2013). TSH stimulates nearly every step along the process of THs 
synthesis and secretion. TSH stimulates the synthesis of NIS, TPO, TG, generation of H2O2, 
internalization of TG by TFCs, its degradation and the subsequent release of THs into the 
blood circulation (Stathatos, 2006).  
The thyroid specific expression of the proteins involved in thyroid hormone synthesis, TG, 
TPO, NIS and PDS requires transcription factors such as NKX2-1 (NK2 Homeobox 1/ also 
known as thyroid transcription factor 1 (TTF-1), FOXE1 (Forkhead Box E1/ also known as 
thyroid transcription factor 2 (TTF-2) and PAX8 (Paired Box 8) (Kambe and Seo, 1997; De 
Felice and Di Lauro, 2004; Fernandez et al., 2015). Binding sites of NKX2-1, FOXE1 and 
PAX8 are present in the promoters of TG and TPO, NKX2-1 and PAX8 in the NIS upstream 
enhancer and NKX2-1 in the promoter of PDS (Damante and Di Lauro, 1994; Di Palma et al., 
2003; Christophe, 2004; Dentice et al., 2005; Portulano et al., 2014).  
1.2. Normal thyroid development 
1.2.1 Key steps of thyroid development   
The thyroid gland originates from a median anlage and two lateral anlages (ultimobranchial 
bodies), which fuses during development (De Felice and Di Lauro, 2004; Szinnai, 2014a). 
The median anlage originates from the foregut endoderm, while the lateral anlages are of 
neuroectodermal origin and derived from the 4th pharyngeal pouches (Szinnai, 2014a). As 
mentioned earlier, the thyroid gland has two distinct cell types: 1) The TFC precursor cells 
that are derived from the foregut endoderm, and 2) C-cells that are derived from the lateral 
anlages. After migrating from their respective sites of origin, cells from both the thyroid 
anlage and the lateral anlages ultimately merge in the definitive thyroid gland. After merging, 
TFCs originating from the thyroid anlage organize into thyroid follicles, whereas the C-cells 
scatter in the interfollicular space (De Felice and Di Lauro, 2004; Nilsson and Fagman, 2013; 
Szinnai, 2014a).   
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All major morphogenetic steps of the thyroid are conserved in humans and mice:  
A) Specification and budding of the thyroid primordium from the foregut endoderm. 
B) Migration of the median anlage to its final pretracheal position. 
C) Fusion of median anlage with the ultimobranchial bodies (lateral anlages). 
D) Terminal differentiation with the onset of thyroid hormone synthesis (De Felice and Di 
Lauro, 2004; Trueba et al., 2005; Fagman et al., 2006; Szinnai, 2007).  
The sequence of these key steps of thyroid development is identical in humans and mice and 
can be correlated (Table 1). 
Table 1: Correlation of the timing of relevant events during thyroid development in humans 
and mice. (E- Embryonic day; GW- Gestational week).  
 
EVENTS HUMAN 
(Embryonic day and 
gestational week) 
MOUSE 
(Embryonic day) 
Specification of the median anlage E22 E8.5 
Budding of the median anlage E26 E9.5 
Migration of median and lateral anlages E28-48 E10.5-13.5 
Fusion of median and lateral anlages E44 E13 
Terminal differentiation E48-80; GW 7-11 E14.5- 16.5 
Follicle formation E73-80; GW 10-11 E15.5 
Onset of thyroid hormone synthesis E80; GW 11 E16.5 
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Figure 3. Transcription factors in the endoderm. The schematic representation of the mouse E8.5–E9.5 gut 
tube shows the expression of the transcription factors Pax8, Foxe1, Nkx2-1, Hhex, and Hes1 along its anterior–
posterior axis and in regions that contribute to other endodermal organs. 
Taken from Szinnai, 2014.  
 
1.2.2 Endodermal origin of the thyroid gland 
Following gastrulation of vertebrate embryos (embryonic day E7.5 in mice), the definitive 
endoderm undergoes complex morphogenetic changes that form primitive gut tube. 
Invagination of the endoderm at the anterior end (the foregut) contributes to the formation of 
thyroid, thymus, parathyroid, pancreas and the liver. The cells of these organs that undergo 
specification and development are controlled by transcriptional regulators and by signals from 
the surrounding tissues such as heart and notochord (Zorn and Wells, 2009; Kraus and 
Grapin-Botton, 2012). Transcription factors that are expressed early in the endoderm, such as 
Foxa1 (Forkhead Box A1), Foxa2 (Forkhead Box A2), Gata4 (GATA binding protein) and 
Gata6 are necessary for the differentiation, survival and morphogenesis of the foregut (Ang 
and Rosant, 1994; Kuo et al., 1997; Morrisey et al., 1998).  
At E8-9.5, the expression of transcription factors such as Foxa1, Foxa2, Hhex 
(hematopoietically expressed homeobox), Pdx1 (pancreatic and duodenal homeobox 1) and 
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Nkx2-1 along the anterior-posterior axis of the ventral foregut marks organ specific domains. 
Foxa1 and Foxa2 are expressed in the ventral foregut in the liver, lung and pancreas field 
(Kaestner et al., 1993; Wan et al., 2005; Lee et al., 2005; Zaret, 2008). Hhex is expressed in 
the forebrain, thyroid and liver (Thomas et al., 1998; Martinez-Barbera et al., 2000). Nkx2-1 
is expressed in the thyroid and lung (Lazzaro et al., 1991; Kimura et al., 1996; Cardoso and 
Lü, 2006). Hes1 (hairy/enhancer of split 1) is expressed in TFC progenitors and pancreatic 
progenitors, while Pax8 and Foxe1 endodermic expression occurs exclusively in the thyroid. 
The endodermal cells of the thyroid domain acquire a specific molecular signature by E8.5 in 
the mouse with co-expression of the transcription factors Pax8, Foxe1, Nkx2-1, Hhex, and 
Hes1 in the mouse (Plachov et al., 1990; Lazzaro et al., 1991; Zanini et al., 1997; Thomas et 
al., 1998; Parlato et al., 2004; Carre et al., 2011; Fernández et al., 2015) (Figure 3).  
1.2.3 Budding and migration of the median thyroid anlage  
By E9.0 in mouse and E22 in human embryo, the median anlage is visible as a thickening of 
the endodermal epithelium in the foregut, which is referred to as thyroid anlage. Thickening 
in a restricted region of a cell layer is an essential event in the generation of signals required 
for the continuation of organogenesis (Kenyon et al., 2003). The thyroid anlage evaginates 
from the floor of the pharynx by E9.5 and E26 respectively. The bud forms a diverticulum 
that starts to migrate caudally into the mesenchyme by E10.5 and E32 respectively. The 
molecular mechanism of thyroid migration remains largely unknown. Epithelial to 
mesenchymal transition, a conserved mechanism of active cell migration in development and 
cancer does not play a role as shown by Fagman et al (Fagman et al, 2003). Until now, only 
Foxe1 has been shown to play a specific role in this process, as 50% of Foxe1-/- embryos 
developed thyroid ectopy (De Felice et al., 1998; Trueba et al., 2005; Nilsson and Fagman, 
2013; Fernández et al., 2015).   
1.2.4 Fusion of the median thyroid anlage with the 
ultimobranchial bodies   
By E12.5 in mouse and E48 in human, the median anlage reaches its definitive pre-tracheal 
position and just before reaching the definitive pretracheal position, the thyroid anlage fuses 
with the ultimobranchial bodies. Between E13.0-13.5 in mouse, the thyroid anlage develops 
into two lobes and a narrow isthmus that connects these two lateral lobes (Trueba et al., 2005; 
Fagman et al., 2006; Kusakabe et al., 2006b). Studies on transgenic mice show that Nkx2-1, 
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Pax8 and Shh (Sonic hedgehog) play an important role for correct symmetrical lobulation of 
the median anlage (Fagman et al., 2004; Amendola et al., 2005). 
1.2.5 Terminal differentiation of the thyroid gland  
Terminal differentiation or functional differentiation is the final step of thyroid development 
and results in the onset of thyroid function. It starts by E14.5 in mouse and 7 gestational 
weeks (GW) in the human, and is completed by E16.5 and 11 GW respectively. Terminal 
differentiation comprises structural and functional changes. Structural changes include 
polarization and adhesion of each TFCs to form thyroid follicles, the functional unit of 
thyroid gland. This is followed by angiogenesis forming a dense three-dimensional capillary 
network around each follicle and functional transition from non-functional TFC precursors to 
mature TFC capable of TH synthesis. Active uptake of iodide, Tg synthesis and H2O2 
generation are the most essential mechanisms for thyroid hormone synthesis (De Felice and 
Di Lauro, 2004; Szinnai, 2014a,b).  
In mouse, thyroid specific genes that are typical of the developmental stage appear according 
to a given temporal pattern: By E14.5 Tg, Tpo, and Tshr genes are expressed; by E16 Nis is 
detected. T4 synthesis starts at E16.5. For thyroid hormone biosynthesis, the precise timing of 
the expression of each of these genes is necessary, indicating that a genetic mechanism must 
be necessary for such a control. However, the key players of such a mechanism are unknown 
(Lazzaro et al., 1991; Zannini et al., 1997; Postiglione et al., 2002; Nilsson and Fagman, 
2013; Szinnai, 2014a).  
In humans, terminal differentiation of the thyroid is completed at 11 GW and is characterized 
by the onset of follicle formation and thyroid hormone synthesis. The three growth stages 
representing the structural differentiation of the human thyroid gland histologically are 
precolloid, a beginning colloid and a follicular growth stage has been described in a historical 
landmark paper by Shepard et al. (Shepard et al., 1964). From 7 to 9 GW in embryos, the 
precolloid stage is found characterized by compact unpolarized TFC precursors. From 10 to 
11 GW, the beginning colloid stage is characterized by the appearance of small follicles 
formed by polarizing TFCs. From 12 GW on, progressive follicular growth occurs (Shepard 
et al., 1964). From the autoradiographic studies, iodide accumulation and thyroid hormone 
synthesis occurs during the beginning colloid stage in fetal thyroid (Shepard, 1967; Olin et al., 
1970). T4 in the fetal thyroid gland is present from GW 11 (Szinnai et al., 2007) and in fetal 
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blood from GW 12 on (Thorpe-Beeston et al., 1991). The onset of iodide uptake in fetal 
thyroid occurs at GW 11 as observed by accidental radioablation of the fetal thyroid in 
pregnant women exposed to radioactive iodide during the first trimester. The molecular 
mechanisms underlying the onset of human thyroid function remained largely unknown 
(Szinnai et al., 2007).  
The human and mouse data suggest that the structural and functional differentiation are 
interdependently linked. The expression patterns of the transcription factors PAX8, NKX2-1 
and FOXE1 in the human embryo are described by Trueba et al. (Trueba et al., 2005), the 
sequence of expression of functional proteins involved in thyroid hormone synthesis in the 
human thyroid during differentiation are then shown by Szinnai et al. (Szinnai et al., 2007). 
Mouse data indicating the precise timing of expression of thyroid specific gene necessary for 
thyroid hormone synthesis suggests a genetic mechanism may be responsible for such a 
control (De Felice and Di Lauro, 2004).    
1.3. Thyroid dysgenesis- abnormal thyroid 
development  
1.3.1 Thyroid dysgenesis causes congenital hypothyroidism 
Congenital hypothyroidism (CH) is defined as the deficiency of thyroid hormones at birth or 
postnatally. Thyroid hormone deficiency at birth is mostly caused either by disorder in thyroid 
gland development (dysgenesis; 80-85% of all cases) or a defect in thyroid hormone 
biosynthesis (dyshormonogenesis; 10-15% of all cases) (Park and Chatterjee, 2005; Rastogi 
and La Franchi, 2010; Szinnai, 2014a). 
The most common signs of CH are umbilical hernia, macroglossia, mottled skin, persistent 
jaundice, wide posterior fontanel and poor feeding (Figure 4). A few infants with CH may 
have a palpable goiter due to TDHG (Grant et al., 1992). Symptoms of CH in the newborns 
include quiet newborns, may sleep longer than normal, hoarse cry, constipation and 
hyperbilirubinemia for more than 3 weeks (Rastogi and La Franchi, 2010). 
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TD includes a spectrum of defects in development of the thyroid gland: thyroid agenesis, 
ectopy or athyreosis, thyroid hypoplasia and pretracheal thyroid without function (Figure 5). 
Agenesis occurs in 20-30% of TD cases, due to defect in survival of TFC precursors. Thyroid 
ectopy involves sublingually located thyroid and occurs in 50-60% of TD cases, due to defect 
in migration of thyroid anlage. Thyroid hypoplasia occurs in 5% of TD cases. Further, 
normally located thyroid without function are the mildest form of TD (10%) (Devos et al., 
1999; Brown and Demmer, 2002; Rastogi and La Franchi, 2010; Szinnai, 2014a). The 
specific form of TD is dependent at what stage of thyroid development the physiological 
process is disrupted (Figure 5).  
 
TD is typically a sporadic disorder, however recent evidence suggests the involvement of 
genetic component. Of all the cases of TD, one study found that 2% were familial in 
occurrence (Castanet et al., 2000). Thus, the underlying cause in most of the cases still 
remains unknown. Mutational screening of cohort of TD patients and phenotypes from 
Figure 4: Signs of congenital hypothyroidism. A - 
3 months old hypothyroid infant with untreated CH 
shows hypotonic posture, wide posterior fontanelle, 
myxedematous facies, macroglossia, and umbilical 
hernia. B – Magnified image of the same patient with 
myxedematous facies, macroglossia, and mottled 
skin. C - Same patient with abdominal distension and 
umbilical hernia. 
Taken from Rastogi, 2010.  
Figure 5: Sequence of processes during normal thyroid development and specific forms of thyroid dysgenesis 
resulting from disrupted development at defined time points. 
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transgenic mouse models has identified mutations in genes that are involved during thyroid 
development. These include TSHR, PAX8, FOXE1 NKX2-1, and TBX21 (Figure 6). These 
genes encode for transcription factors that are expressed during thyroid development and in 
the normal functioning of adult thyroid. Mutations in these genes are found only in a small 
percentage of TD patients (Sunthornthepvarakul et al., 1995; Abramowicz et al., 1997; 
Clifton-Bligh et al., 1998; Macchia et al., 1998; Vilain et al., 2001; Krude et al., 2002; 
Pohlenz et al., 2002; De Felice and Di Lauro, 2004; Dentice et al., 2006; Moya et al., 2006; 
Al Taji et al., 2007; Ferrara et al., 2008).  
Figure 6: Sequence of genes identified in normal thyroid development in human and mouse and their specific 
time points of identification. 
 
1.3.2 Thyroid dyshormonogenesis  
Genetic defects in each of the various steps involved in the biosynthesis of THs are the cause 
of CH due to thyroid dyshormonogenesis (TDHG). These include defects in iodide transport 
due to mutations in sodium iodide symporter gene (NIS or SLC5A5) (Stanbury and Chapman, 
1960; Fujiwara et al., 1997), partial defects in the organification of iodide (PIOD) leading to 
Pendred syndrome (PDS) (Morgans and Trotter, 1958; Everett et al., 1997; Kopp and 
Bizhanova, 2011), defects in iodination and coupling of tyrosyl moieties due to mutations in 
thyroid peroxidase (TPO) gene (Avbelj et al., 2007), mutations in the gene encoding DUOX2 
(Knobel and Medeiros-Neto, 2003; Grasberger, 2010; Fugazzola et al., 2013) and in the gene 
encoding for the dual oxidase maturation factor 2 (DUOXA2) (Zamproni et al., 2008) leads to 
dyshormonogenesis due to H2O2 deficiency, inactivating mutations of the TG gene causes 
defects in thyroglobulin synthesis (Rivolta et al., 2005; Targovnik et al., 2010), and mutations 
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in iodotyrosine deiodinase (DEHAL1, IYD) leads to iodotyrosine deiodinase deficiency 
associated with defective intrathyroidal iodide recycling and excessive blood and urinary 
secretion of MIT and DIT (Moreno et al., 2008).  
1.3.3 Insights from transgenic mouse models 
Pax8  
Gene encoding Pax8 (mouse Pax8 and human PAX8) is located on chromosome 2 (Plachov et 
al., 1990; Stapleton et al., 1993). It is expressed in the thyroid, kidney and in the 
myelencephalon (Plachov et al., 1990). It binds to the specific DNA sequences in the 
promoter region of Tg, Tpo and Nis and is detected at E8.5 in the developing murine thyroid. 
Its expression is maintained in TFCs during all the stages of thyroid development and in adult 
thyroid (De Felice and Di Lauro, 2004).  
Heterozygous Pax8+/- mice show no phenotype, whereas homozygous Pax8-/- mice show 
growth retardation and die within 2–3 weeks. In Pax8-/- mice, the thyroid gland shows neither 
follicle formation nor TFCs and is composed only of C-cells. These mice die due to 
hypothyroidism and administration of T4 helps them to survive. At E12.5 in Pax8 null 
embryos, the TFCs are absent after normal budding and migration process. Thus, Pax8 is 
necessary for thyroid precursor cell survival and for thyroid development and functional 
differentiation (Plachov et al., 1990; Mansouri et al., 1998; Magliano et al., 2000; Fernández 
et al., 2015). 
Heterozygous mutations in PAX8 cause athyreosis or thyroid hypoplasia. Since PAX8 is also 
expressed in the mesonephros and ureteric buds, there are cases of genitourinary 
malformations in patients with CH (Kumar et al., 2009).  
Foxe1 
Gene encoding Foxe1 is located on chromosome 4 in mouse (Zannini et al., 1997) and on 
chromosome 9 in humans (Chadwick et al., 1997). It recognizes a DNA sequence present on 
both Tg and Tpo promoters under hormone stimulation (Civitareale et al., 1989) and is 
expressed in the developing thyroid, tongue, epiglottis, esophagus and palate (Dathan et al., 
2002).  
Foxe1-/- mice show either athyreosis or an ectopic thyroid, elevated TSH levels and die within 
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first 2 days of birth. In these mice, thyroid budding occurs normally, however thyroid 
migration is not initiated. These non-migrating cells differentiate and synthesize Tg. Thus, 
Foxe1 is essential for migration and survival of TFC precursors (Zannini et al., 1997; De 
Felice et al., 1998; Fernández et al., 2015). 
Patients born with a homozygous missense mutation in FOXE1 causes a Bamforth-Lazarus 
Syndrome of CH characterized by thyroid dysgenesis (mostly athyreosis), bifid epiglottis, 
choanal atresia, cleft palate, spiky hair and with or without facial dysmorphism and 
porencephaly (Clifton-Bligh et al., 1998; Castanet et al., 2002; Vieira et al., 2005).  
Nkx2-1 
Nkx2-1 belongs to the Nkx2 family of transcription factors (Price et al., 1992) and was 
identified as nuclear protein able to bind the specific DNA sequences in the promoter region 
of Tg (Guazzi et al., 1990) and enhancer region of TPO (Mizuno et al., 1991). Mouse Nkx2-1 
is located on chromosome 12, whereas the human NKX2-1 is on 14q13 (Civitareale et al., 
1989; Guazzi et al., 1990; De Felice and Di Lauro, 2004). Nkx2-1 is expressed in the 
precursors and differentiated TFCs and C-cells (Suzuki, 1998), adult thyroid, lung epithelium, 
posterior pituitary and in the forebrain.  
Nkx2-1-/- mice show athyreosis with absence of TFCs and C-cells, impaired lung 
morphogenesis, lack of pituitary, alteration in the forebrain and death at birth (Kimura et al., 
1996). At E11 in Nkx2-1-/- embryos, no thyroid cells are detectable. This data and the 
presence of apoptotic cells suggest that Nkx2-1 is necessary to prevent the initiation of 
apoptosis (Kimura et al., 1999). Nkx2-1+/- mice have normal thyroid size, but showed 
decreased coordination and mild hyperthyrotropinemia. Disturbed follicular architecture and 
function is seen in adult thyroid of the conditional knockout mice (Kusakabe et al., 2006a; 
Fernández et al., 2015).  
Mutations in NKX2-1 causes brain-lung-thyroid syndrome characterized by congenital 
hypothyroidism, infant respiratory distress syndrome (IRDS), ataxia and benign chorea 
(Krude et al., 2002; Willemsen et al., 2005; Moya et al., 2006). 
Hhex  
Gene encoding Hhex (Hematopoietically expressed homeobox) is located on chromosome 19 
in mouse (Ghosh et al., 1999) and on chromosome 10 in humans (Hromas et al., 1993). Hhex 
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is expressed in the primitive endoderm and from E8.5 onwards in the primordium of thyroid, 
thymus, pancreas, liver, foregut and lungs. Hhex is highly expressed in developing and adult 
thyroid (Thomas et al., 1998; Bogue et al., 2000).  
Hhex-/- mice show severe defects during the development of the liver, the thyroid, the 
forebrain and the heart. In thyroid, Hhex is an early marker of thyroid cells and is essential for 
thyroid morphogenesis as observed in Hhex-/- embryos where the development of the thyroid 
is arrested at the thyroid bud stage at E9.5 (Barbera et al., 2000).  
Hes1 
Hes1 encodes for a basic Helix-Loop-Helix (bHLH) transcriptional repressor regulated by the 
Notch pathway (Kageyama et al., 2007). It regulates the morphogenesis of various tissues by 
maintaining the undifferentiated progenitor state by negatively regulating bHLH transcription 
factors such as Mash1 in the nervous system and Ngn3 in the pancreas. Hes1 was detected 
from E9.5 onwards in the median anlage, and at E11.5 in the ultimobranchial bodies during 
normal mouse thyroid development (Carré et al., 2011).  
 
Hes1−/− mice embryos showed severe neuronal developmental defects and pancreatic 
hypoplasia (Ishibashi et al., 1995; Murata et al., 2005). Furthermore, thyroid hypoplasia and 
abnormal fusion of the thyroid anlagen is observed in Hes1−/− mutants (Carré et al., 2011). It 
is shown that Hes1 regulates the number of progenitors of thyrocytes and C-cells present in 
both thyroid anlagen and is involved in determining the normal size of the thyroid gland. 
Reduced endocrine thyroid function in both, the thyrocytes and the C-cells was observed, as 
demonstrated by a profound decrease in both T4 and calcitonin positive surface areas. Thus, 
they have shown that Hes1 is crucial for normal mouse thyroid organogenesis as it assures the 
proper fusion of the thyroid anlagen.  
 
Tshr 
Gene encoding Tshr is located on chromosome 12 in mouse (Taylor et al., 1996) and on 
chromosome 14 in humans (Libert et al., 1990) and encodes for a G protein coupled receptors 
(Parmentier et al., 1989). Expression of Tshr is seen in TFCs from E15.5 in mouse and is 
profoundly upregulated by E17-E18. The expression pattern of Tshr mRNA is coincident with 
the completion of migration process, up-regulation of thyroid specific genes, beginning of 
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colloid formation and folliculogenesis (Vassart and Dumont, 1992; Postiglione et al., 2002). 
Thyroid hypoplasia with severe hypothyroidism in adult thyroid is seen in Tshrhyt/hyt mice, 
which is characterized by a spontaneous loss-of-function mutation in Tshr gene, and in Tshr-/- 
mice. Expression of Tpo and Nis is down regulated, but Tg expression is slightly decreased in 
these mice (Stein et al., 1994; Marians et al., 2002).  
Mutations in the TSHR result in resistance to TSH, which causes a reduction in thyroid 
hormone production, athyreosis or thyroid hypoplasia and normal thyroid with severe 
hypothyroidism (Sunthornthepvarakul et al., 1995; Refetoff, 2003). Loss-of-function 
mutations in the TSHR gene are inherited in an autosomal dominant way and lead to euthyroid 
hyperthyrotropinemia and severe CH (Refetoff, 2003; Beck-Peccoz et al., 2006). 
1.3.4 Alternative mechanisms for TD 
TD cases due to mutations in NKX2.1, PAX8, TSHR, FOXE1 and NKX2-5 are very few. 
Genetic linkage analysis of these genes showed no significant LOD (logarithm (base 10) of 
odds) scores in a large cohort of multiplex families. Therefore, other mechanisms are 
suggested for the vast majority of TD cases (Clifton-Bligh et al., 1998; Macchia et al., 1998; 
Castanet et al., 2002; Castanet et al., 2005; Al Taji et al., 2007; Narumi et al., 2010). 
Multigenic origin of TD 
The evidence for the multigenic origin of TD in mice has been provided by Amendola et. al 
(Amendola, 2005). Pax8 and Nkx2-1 double heterozygous mice (Pax8+/-Nkx2-1+/-) exhibited 
severe TD with thyroid hypoplasia and hemiagenesis, while both single heterozygous mice 
had no TD phenotype (Amendola et al., 2005). 
In humans, multiple loci responsible for the pathogenesis of TD have been suggested. Few 
patients with digenic origin of TD are reported. Mutations in TSHR in combination with 
mutations in DUOX2 (Narumi et al., 2011a), TPO (Sriphrapradang et al., 2011) and GNAS 
(Lado-Abeal et al., 2011) have been shown. One case with mutation in PAX8 and NKX2.5 has 
been shown (Hermanns et al., 2011). However, no TD cases with digenic defects were 
identified in either a cohort of 170 Czech patients with TD (Al Taji et al., 2007) screened for 
all known genetic aberrations in genes encoding for PAX8, NKX2.1, FOXE1, NKX2.5, 
HHEX and TSHR. Only one patient has exhibited digenic cause of TD from the cohort of 102 
Japanese patients with CH (Narumi et al., 2010). This suggests that genes that are not 
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associated with TD might be responsible for the pathogenesis of TD. 
Early somatic mutations 
Somatic mutations are recently shown to cause congenital neurological disease (Poduri et al., 
2013). Somatic loss-of-function mutation has to occur very early during the developmental 
process in the common ancestral cell of all the cells committed to the thyroid fate to lead to a 
phenotype (Deladoëy et al., 2007). Until now, a somatic heterozygous mutation in PAX8 has 
been reported in a female patient and her two siblings having TD due to a germ line mutation 
in PAX8 (Narumi et al., 2011b). The patient had normal thyroid function but underwent 
hemithyroidectomy due to a thyroid adenoma. Histological analysis of the patient’s thyroid 
revealed adenoma tissue, embryonic thyroid tissue in the follicular growth stage and normal 
thyroid tissue. Since somatic mutation was only observed in tissue with embryonic features 
and not in normal or adenoma tissue, it indicates the existence of early somatic mutations. 
Apart from thyroid, PAX8 mutation was also observed in lymphocytes and nails that are 
derived from mesoderm and ectoderm respectively, suggesting its early occurrence during 
embryogenesis (Narumi et al., 2011b).  
Copy number variations  
Recently, an increasing number of copy number variations (CNVs) associated with congenital 
human diseases have been reported (Erdogan et al., 2008; Hitz et al., 2012; Southard et al., 
2012). To determine the role of CNVs in the etiology of TD, Thorwarth et al. have screened 
80 TD patients and two pairs of discordant monozygotic twins (Thorwarth et al., 2010). Of all 
patients screened, 8.75% of the patients with athyreosis and hypoplasia had shown potential 
nonrecurrent CNVs, six duplications and four deletions. However, no CNV encompassed 
genes known to be involved in thyroid morphogenesis. No differences in CNVs between the 
affected and the healthy twins were found in the two pairs of monozygotic twins discordant 
for TD. In another study by Abu-Khudir (Abu-Khudir et al., 2010), CNVs were assessed in 
three human ectopic thyroid tissues in combination with gene expression analysis. Though the 
gene expression studies showed differences in normal and ectopic thyroids, these differences 
were independent of the identified thyroid specific CNVs. Thus, high frequencies of CNVs in 
screened TD patients suggest the involvement of CNVs in the pathogenesis of TD. However, 
lack of recurrence, absence of differences in CNVs in monozygotic discordant twins and lack 
of gene expression dependence on CNVs in ectopic thyroid tissues suggests that CNVs do not 
play a major role in the pathogenesis of TD (Abu-Khudir et al., 2010).  
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Epigenetic mechanisms  
Apart from monogenic, multigenic, somatic mutations and CNVs, epigenetic mechanisms 
such as DNA methylation and histone modifications might play a role in the pathogenesis of 
TD. High discordance rate (92%) between the monozygotic twins and the non-Mendelian 
mechanisms that are consistent with the sporadic occurrence of TD in majority of the cases 
(98%) strongly suggests that epigenetic mechanisms need to be investigated to confirm their 
involvement in TD (Perry et al., 2002; Vassart and Dumont, 2005; Deladoëy et al., 2007). 
Epigenetic mechanisms involving aberrant modifications by histone acetylation or 
methylation have been shown to change gene expression in thyroid cancer cells (Kondo et al., 
2008; Russo et al., 2011). Their role in TD remains unknown.  
1.4. Epigenetic regulation during embryonic 
development 
1.4.1 Definition of epigenetics 
Conrad Waddington coined the term “Epigenetics” in 1940 and defined it as the study of 
causal interactions between genes and their products that bring the phenotype into being. The 
definition of epigenetics has changed over the years and currently is defined as the study of 
mitotically and/or meiotically heritable changes in gene function that do not undergo a change 
in DNA sequence (Dupont et al., 2009). The basic building block of chromatin is the 
nucleosome. 146-147 base pairs of DNA wraps around a histone octamer that is composed of 
one (H3–H4) tetramer capped by two H2A–H2B dimers and each octamer is linked to other 
by the linker histone H1. This forms the nucleosome (Luger, 1997). Modifications of DNA 
and histones alter the accessibility of DNA to transcription machinery and therefore influence 
gene activity and expression (Jaenisch and Bird, 2003; Grewal and Moazed, 2003; Reik, 
2007).  
1.4.2 Different forms of epigenetic regulation 
DNA methylation 
DNA methylation involves covalent addition of a methyl group to cytosine bases and occurs 
mainly on CpG islands. DNA methylation is initiated (de novo methylation) and maintained 
by the enzymatic activity of the DNA methyltransferases (DNMTs) (Goll and Bestor, 2005). 
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DNMT enzymes DNMT3A and DNMT3B set up a new methylation pattern on the 
unmodified DNA molecules during development and hence are called as de novo DNMTs 
(Okano, 1999). The promoter regions of silenced genes possess significantly more methylated 
cytosines as compared with actively transcribed genes. Thus, the canonical function of DNA 
methylation is to mediate transcriptional repression at promoter elements (Reddington et al., 
2013).  
MicroRNAs  
Recently, MicroRNAs (miRNAs) have been established as important mediators of gene 
regulation. Endogenous miRNAs have been shown to play an important role in developmental 
processes, including differentiation, proliferation, and apoptosis (Ambros, 2004) and regulate 
expression at posttranscriptional level. Further, it has been shown that during embryonic 
development, miRNA expression is tissue specific, which implicates that they are important 
to establish and maintain cell type and tissue identity (Giraldez et al., 2005; Wienholds et al., 
2005; Zhang et al., 2015).  
Histone modifications and histone code   
The flexible N-terminal tail of histones undergoes several post-translational modifications, 
such as acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP 
ribosylation, glycosylation and carbonylation (Bernstein et al., 2007; Kouzarides, 2007; 
Kurdistani, 2007). Histone acetylases (HATs), histone deacetylases (HDACs), histone 
methyltransferases (HMTs) and histone demethylases are few examples of enzymes 
responsible for histone modifications. The highly dynamic changes in the chromatin structure 
takes place during many fundamental cellular processes, like gene transcription, DNA 
replication or DNA damage. The type and position of modification over histone residue 
determines the chromatin state as euchromatic or heterochromatic. The ‘histone code’ 
hypothesis states that a combination of various modifications over histone residues allows the 
gene expression status to interchangeably switch between on and off and regulate chromatin 
structure (Strahl and Allis, 2000; Jenuwein and Allis, 2001; Margueron et al., 2005).  
1.4.3 Histone acetylation  
Histone proteins have N- and/or C-terminal tails that extend out from the core surface and 
undergo various post-translational modifications, such as acetylation, methylation, 
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phosphorylation, ubiquitination, and sumoylation. These post-translational modifications of 
the residues on the histone tails make them an important switch points for chromatin 
condensation or decondensation, thus altering their interactions with DNA and nuclear 
proteins. Out of all the histone H2A, H2B, H3 and H4 tails, the histone H3 N-terminal tail is 
the most extensively studied and modifications on residues K4, K9, and K27 have the most 
significant effect on transcriptional regulation (Figure 7). K4, K9 and K27 can be methylated 
and acetylated (Strahl and Allis, 2000). 
 
Figure 7. Schematic diagram of the covalent post-translational modifications of histone H3 N-terminal 
tail. The different modifications are indicated (ac, acetylation; me/me/me3 as mono/di/tri-methylation, with 
green and red indicating marks that are associated with activation and repression, respectively. 
Sanjay Gawade, Unpublished data. 
 
Acetylation of histones on lysine residues is a dynamic reversible process controlled by 
histone deacetylases (HDACs) and histone acetyltransferases (HATs) (Figure 8). The balance 
between these two processes together with other proteins and DNA modifications such as 
DNA methylation regulates chromatin accessibility and gene expression. HATs regulate gene 
activation by adding acetyl groups to the histones that leads to a change in the net positive 
charge of histone tails causing chromatin relaxation (Chen et al., 2001; Roth et al., 2001; Xu 
et al., 2007). HDACs regulate gene silencing by removing acetyl groups from histones and 
thus interact more closely with the DNA causing chromatin condensation (Roth and Allis, 
1996; Svaren and Hörz, 1993). HDACs also deacetylate non-histone proteins, such as 
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transcription factors like E2F1  (Martinez-Balbas et al., 2000), p53  (Luo et al., 2000) and the 
cytoskeletal protein tubulin (Hubbert et al., 2002; Glozak et al., 2005). 
In humans, 18 HDACs have been identified and are divided into four classes based on their 
homology to yeast HDACs, their subcellular localization and their enzymatic activities 
(Thiagalingam et al., 2003): 
A) The class I HDACs (HDAC1, HDAC2, HDAC3 and HDAC8) has homology to the yeast 
RPD3 protein and can generally be detected in the nucleus.  
B) Class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10) have 
homology to the yeast Hda proteins and can be detected in nucleus and the cytoplasm.  
C) The class III HDACs, also called as Sirtuins (SIRTl, 2, 3, 4, 5, 6 and 7) are homologues of 
the yeast protein Sir2 and require NAD+ for their activity.  
D) HDAC11 is the sole member of class IV HDACs.  
HDACs contain zinc in their catalytic site and are inhibited by drugs such as trichostatin A 
(TSA) and vorinostat [suberoylanilide hydroxamic acid (SAHA)] except sirtuins, which do 
not contain zinc in their catalytic site and are not inhibited by either TSA or vorinostat 
(Grozinger and Schreiber, 2002; Dokmanovic et al., 2007; Marks and Xu, 2009). Drugs like 
TSA and SAHA are part of histone deacetylase inhibitors (HDACi) as they inhibit the action 
of HDACs. HDAC knockout mice studies have provided highly specific information about 
the functions of individual HDACs in development and disease (Table 2).  
HATs and HDACs play a very vital role in developmental processes and normal physiology, 
and their deregulation is linked to disease states. Deletion of each member of the class I 
HDAC family leads to lethality, indicating a unique role of each HDAC in development 
(Haberland et al., 2009a). Typically HDACs are present within multi-subunit protein 
complexes together with other components that determine HDAC target gene specificity due 
to the interactions with sequence-specific DNA-binding proteins (Cunliffe 2008; Yang and 
Seto, 2008). These complexes may be made up of one or more HDACs. Without binding to 
DNA directly, HDACs are part of multi protein complexes that include co-repressors and 
coactivators, which interact with DNA (Xu et al, 2007). Class I HDACs are found in 
repressive complexes known as the Sin3, NuRD, CoREST and NCoR/SMRT complexes 
(Yang and Seto, 2008). 
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Figure 8. Schematic of the reversible histone acetylation changes in chromatin organization. HATs- 
Histone acetyl transferases, HDACs- Histone deacetylases. Acetyl residues from acetyl-CoA are added by HATs 
on lysine residues of the histone tails that results in active chromatin, whereas removal of acetyl residues by 
HDACs results in repressed chromatin. 
Sanjay Gawade, Unpublished data. 
 
 
Table 2: Classification of histone deacetylase (HDAC) superfamily, time point of lethality of 
the knockouts and loss-of-function phenotypes in mice.  
(E- embryonic day; P- days postnatal)  
Adapted from Haberland et al. (Haberland et al., 2008).  
 
Class HDACs Time of 
lethality 
Phenotype 
Class I HDAC1 E10.5 Proliferative defects  
(Lagger et al., 2002) 
 HDAC2 P1 Cardiac malformations 
(Trivedi et al., 2007) 
 HDAC3 E9.5 Gastrulation defects 
(Bhaskara et al., 2008) 
 HDAC8 P1 Craniofacial defects 
(Haberland et al., 2009b) 
Class IIa HDAC4 P7-P14 Chondrocyte differentiation defect in growth 
plate 
(Vega et al., 2004) 
 HDAC5 Viable Exacerbate cardiac hypertrophy after stress 
(Chang et al., 2004) 
 HDAC7 E11 Endothelial dysfunction 
(Chang et al., 2006) 
 HDAC9 Viable Exacerbate cardiac hypertrophy after stress 
(Zhang et al., 2002) 
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Class IIb HDAC6 Viable Increased tubulin acetylation 
(Zhang et al., 2009) 
 HDAC10 Not 
determined 
- 
Class IV HDAC11 Not 
determined 
- 
 
1.4.4 Epigenetic regulation by histone deacetylases during 
development and function    
Class I members HDAC1 and HDAC2 are highly homologous (Tsai and Seto, 2002). Murine 
genes Hdac1 and Hdac2 are closely related and encode two enzymes with high sequence 
similarity (Khier et al., 1999). Global knockout of HDAC1 is lethal at E10.5 and embryos 
show growth retardation, disturbed head formation and proliferative defects (Lagger et al., 
2002; Montgomery et al., 2007). Global knockout of HDAC2 is lethal at postnatal day 1 and 
shows cardiac malformations (Montgomery et al., 2007; Trivedi et al., 2007). Class I HDACs 
seem to play a primary role in cell survival and proliferation based on selective gene knockout 
studies, whereas class II HDACs have tissue specific roles (Lagger et al., 2002; Marks and 
Xu, 2009). HDAC1 and HDAC2 are involved in various developmental processes like 
neurogenesis, myogenesis, haematopoiesis and epithelial cell differentiation (Brunmeir et al., 
2009). HDAC inhibitors (HDACi) are being used in various tissue culture models to 
investigate the role of HDACs for development and differentiation in various organs. Ex vivo 
studies on mouse intestine showed that class I HDACs are confined to the prospective 
epithelium. The levels of class I HDACs decline coincidently with the activation of 
differentiation genes. HDAC inhibitors activated the same genes prematurely and caused 
accelerated cytodifferentiation. Overexpression of HDAC1 and HDAC2 in these ex vivo 
cultures reversed expression of certain maturation markers (Tou et al., 2004). Ex vivo studies 
on rat pancreas showed modification in cell fate of pancreatic progenitor cells in endocrine 
and exocrine differentiation in the presence of HDACi (Haumaitre et al., 2008).  
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1.4.5 Role of epigenetic regulation for normal thyroid 
development and in thyroid dysgenesis 
As stated before, the following arguments suggests a role of epigenetic regulation of thyroid 
development; a) Very low identified monogenetic forms of TD, b) Discordance of 
monozygotic twins for TD, c) Epigenetic changes during thyroid carcinogenesis. However, 
information on the role of epigenetic regulation for thyroid development by using knockout 
mice models has never been described.  
 
Abu-Khudir et al assessed the role of altered DNA methylation profiles in the pathogenesis of 
TD by comparing ectopic thyroid tissue from TD patients with euthyroid tissues (Abu-Khudir 
et al., 2010). No difference in promoter and CpG island methylation profiles between the two 
tissues was observed. Also, correlation between the global DNA methylation profile and the 
differential expression in the tissues revealed no difference. However, clusters of genes that 
are repressed in ectopic tissues, involved genes incorporated in histone modifications. 
Therefore, role of differential histone modifications in the observed differential gene 
expression in ectopic thyroids cannot be excluded (Abu-Khudir et al., 2010).  
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2. AIM OF THE THESIS 
 
The aim of this thesis work is to address the following unsolved questions in the context of 
molecular mechanisms of normal and abnormal thyroid development:  
 
Aim of Project 1: A new tool for thyroid research: Flow cytometry of the thyroid gland 
 
The thyroid is composed of endocrine epithelial cells, blood vessels and mesenchyme. 
Fluorescence-activated cell sorting (FACS) provides a tool for quantification of distinct cell 
populations. However, in the absence of an established tissue-specific protocol, no data exist 
on absolute cell numbers, relative distribution, and proliferation of the different cell 
populations in the developing and mature thyroid. 
 
The aim of this project was to identify and quantify various cell populations in developing 
and adult mouse thyroids by establishing a new flow cytometry protocol.  
 
Aim of Project 2: A new hypothesis: Epigenetic regulation of thyroid development 
 
In the differentiating tissues, reversible histone acetylation represents a major epigenetic 
mechanism regulating gene expression. Acetylation of core histones is regulated by histone 
deacetylases and histone acetyltransferases in a reciprocal way.  
 
Abnormal thyroid development results in TD. Several observations from clinics and biology 
suggest epigenetic regulation of thyroid development: 1) Discordance of monozygotic twins 
for TD, 2) disrupted histone acetylation in thyroid cancer being associated with loss of 
differentiation markers, and 3) pathologic development of organs after genetic deletion or 
pharmacological inhibition of histone deacetylases (HDAC). 
 
The aim of this study was to analyze the role of HDACs and of histone acetylation for 
regulation of normal thyroid development. 
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3. MATERIALS AND METHODS 
3.1 Mice 
Wild type, outbred, male and female Swiss albino mice were obtained from Janvier Labs, 
Saint Berthevin Cedex, France and were used for all the experiments. All experiments were 
performed in accordance with the federal regulations. 
 
3.2 Thyroid culture, HDACi / HATi treatments 
inhibition of angiogenesis 
 
Figure 9. Murine thyroid culture model. In vivo, undifferentiated E13.5 mouse thyroid starts to undergo 
differentiation and angiogenesis. At E15.5, onset of thyroid follicle formation takes place and at E17.5 the 
thyroid is terminally differentiated. The ex vivo thyroid explant culture model recapitulates the developmental 
stages in vivo. E13.5 thyroids from mice are micro-dissected and cultured at air-surface medium for 3 days 
(E13.5+3d) that represents E15.5 in vivo and 7 days (E13.5+7d) that represents E17.5 in vivo. 
 
After dissecting the E13.5 thyroids from the embryos, these were laid on 0.45 uM ﬁlters 
(Millipore) at the air-medium interface in petri dishes containing IMDM with 25 mM HEPES, 
10% fetal calf serum, L-glutamine, Kanamycyin and 2 Mercaptoethanol 50 mM (Figure 9). 
Two thyroids were places together to form one thyroid explant. Thyroid stimulating hormone 
(TSH) was added to the culture medium to a ﬁnal concentration of 100uU/ml. The explants 
were maintained at 37°C in humidiﬁed 95% air-10% CO2 for 3 days (E13.5+3d) or 7 days 
(E13.5+7d). The medium and TSH were changed after every 48 h. 
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Explants were cultured in the presence of Histone deacetylase inhibitor (HDACi) Valproic 
acid (VPA- Sigma) or absence of VPA (Control). The optimal concentrations of VPA was 
decided by testing increasing doses of VPA (from 0.5 mM to 1.5 mM). VPA 1 mM was 
chosen for all the experiments as these concentrations led to phenotypic effects without any 
toxic effects. Untreated explants were used as control. 
 
To check the effect of inhibition of angiogenesis during thyroid development, thyroid 
explants were treated with angiogenesis inhibitor Sunitinib 1uM (Selleckchem, USA) for 3 
and 7 days. 
 
3.3 Morphometric analysis 
For the analysis of thyroid explant size and total number of thyroid follicles, cryosections of 
the explants were stained with Hematoxylin and Erythrosin B (HE). Thyroid explants were 
embedded in OCT (CellPath, Mid Wales, UK) using isopentane cooled in dry ice and stored 
at -800C at the end of 3 and 7 days. 10um thick cryosections were sliced in a Leica CM 3050 
cryostat (Leica instruments GmbH, Nussloch, Germany), collected on SuperFrost-plus 
microscope slides and stored at -800C until use. For HE staining, slides were ﬁrst air dried for 
1 h at room temperature (RT). Tissue sections were ﬁxed with 4% paraformaldehyde (PFA) at 
RT and washed with PBS. Sections were stained with Hematoxylin for 5 mins at RT and 
washed with lukewarm running tap water for 5 mins. Next, slides were counterstained with 
Erythrosin B for 5 mins at RT and washed in distilled water followed by serial washes with 
70%, 95% and 100% ethanol. Slides were then mounted with entellan mounting medium 
(Merck KGaA, Darmstadt, Germany) and observed under Nikon Eclipse E600. At least 2 
sections of each culture were photographed and further analyzed by ImageJ (version 1.45s, 
NIH, USA). 
 
3.4 Immunohistochemistry 
Immunohistochemistry was performed on frozen sections. Antibodies against NKX2-1 (clone 
8G7G3/1, mouse monoclonal) was obtained from Dako, PECAM (390, rat monoclonal) from 
Biolegend, and Histone H3K9 acetyl, H3K9 tri methyl, HDAC1 from Abcam. Cryosections 
of thyroid explants were air dried for 30 mins before ﬁxing with 4% PFA for 10 mins at RT. 
Slides were washed 3 times with PBS. Antigen retrieval was performed using 10mM sodium 
citrate (pH 6.0) with 0.05% Tween-20 in a pressure cooker for 5 mins at 1200C. Once the 
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slides cooled down to room temperature, sections were washed with PBS with 0.1% Tween 
(PBST) followed by blocking, with blocking solution consisting of 10% goat serum in PBST 
for 1 h at RT. Sections were labeled overnight with primary antibody diluted in blocking 
solution, in a moist chamber in dark, and then the reaction was stopped by rinsing 3 times 
with PBST. The next step of the staining procedure was incubation with secondary antibody 
for 45 mins at RT and rinsing with PBST. Nuclei were stained with DAPI (Sigma, 1ug/ml). 
Slides were then mounted with hydromount mounting medium (National Diagnostics, USA) 
and observed under Zeiss 510 Meta Laser Scanning Microscope. 
 
For the detection of BrdU labeled cells another protocol was followed. Ex vivo BrdU labeling 
of thyroid explants was done by adding BrdU (BD Pharmingen; ﬁnal concentration of 10uM) 
for 2 h before snap freezing the tissues. Tissue sections were ﬁxed with 4% PFA for 30 mins 
at 40C. Slides were washed with 0.1M Phosphate Buffered Saline (PBS) (pH 7.4) with 1% 
TritonX100 (PBST). Sections were incubated with HCl (1M) for 10 mins on ice to break open 
the DNA structure of the labeled cells followed by HCl (2 M) for 10 min at room temperature, 
then 20 min at 37°C. Sections were neutralized by incubating with 0.1 M borate buffer pH 8.5 
for 10 mins at RT. Slides were washed with PBST and blocked with 5% goat serum in PBST 
containing 1M glycine for 1 h. Sections were then incubated overnight in a moist chamber at 
RT with anti BrdU FITC labeled antibody. After washing the slides with PBST, nuclei were 
stained with DAPI (Sigma, 1ug/ml) and slides were mounted with hydromount. 
 
3.5 Cell suspension preparation and flow cytometry 
Embryonic thyroids from E13.5, E15.5, E17.5 embryos and adult thyroids were micro-
dissected, cleaned of fat and connective tissue and placed on ice cold PBS 2%FCS (Phosphate 
Buffer Saline containing 2% Fetal Calf Serum). All embryonic and adult thyroid tissues were 
micro-dissected on the same experimental day. Each experiment represents pooled tissues to 
get enough cells for analysis: E13.5 n≥20 pooled thyroids per sample, E15.5 n≥13 pooled 
thyroids per sample, E17.5 n≥11 pooled thyroids per sample and adult tissues n≥1 thyroid per 
sample. To reduce experimental variations as much as possible, for each analysis all 4 stages 
were analyzed within the same experiment on the same day.  
 
Thyroids were enzymatically digested with 1 mg/ml collagenase/dispase and 2 ug/ml DNase I 
(Roche Diagnostics, Switzerland) at 370 C for 20 minutes until single cell suspension was 
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obtained. Adult thyroids were ﬁrst cut into small pieces using sterile scissors before 
enzymatic digestion. After obtaining the single cell suspension, cells were spun down with 
PBS 2%FCS for 5 minutes at 1500 rpm. Cells were then stained with cell surface markers for 
20 mins on ice. 
 
Prior to intracellular staining, cells were ﬁxed and permeabilised using the BD 
Cytoﬁx/CytopermTM Fixation/Permeabilization solution kit (BD Bioscience) according to 
the manufacturer’s guidelines. Cells were then treated with 10% goat serum for 45 mins at 
room temperature. Intracellular staining with anti- NKX2-1 antibody was done for 45 mins at 
room temperature followed by secondary antibody for 30 mins at room temperature. Non-
nucleated cells were excluded by staining with DAPI; (4’,6-Diamidine-2’-phenylindole 
dihydrochloride; Roche Diagnostics, Switzerland). 
 
Cells were acquired on BD FACSAria II ﬂow cytometer (Becton Dickinson, Mountain View, 
CA). FlowJo software (Tree Star Inc., Ashland, OR, USA) was used for analyzing ﬂow 
cytometry data. 
 
3.6 Antibodies for flow cytometry 
3.6.1 Primary antibodies 
mAb for EpCAM (clone G8.8), PDGFRa (APA5), CD45 (30-F11), Ter119 (TER-119), CD54 
(YN1/1.7.4) and PECAM (390) were obtained from Biolegend. NKX2-1 (EP1584Y), Histone 
H3, H3K9ac, H3K9me3, HDAC1 (10E2) and HDAC2 (Y461) were obtained from Abcam. 
5’-bromo-2’-deoxyuridine (BrdU) and 7-amino-actinomycin D (7-AAD) were obtained from 
BD Pharmingen (BD Pharmingen BrdU Flow kit). 
3.6.2 Secondary antibodies  
Goat anti rabbit or mouse anti rabbit antibodies conjugated with either A647 or A488 were 
obtained from Life technologies.  
 
3.7 Absolute cell number calculation 
To calculate the absolute cell numbers, all events acquired were ﬁrst gated to remove cell 
debris by using forward-scattered light (FSC) and side-scattered light (SSC). Then, cell 
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doublets were removed by using SSC- height (SSC-H) and SSC- width (SSC-W). 
Erythroblasts/ Erythrocytes were further removed by gating out Ter119 positive cells. Organ 
cellularity was determined with a Z1 Coulter Counter (Beckman Coulter). The absolute cell 
number of each cell type was calculated by multiplying organ cellularity with the frequency 
of individual cell populations determined by ﬂow cytometry. 
 
3.8 Apoptosis 
3.8.1 TUNEL assay 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was 
performed on thyroid explants according to manufacture’s instructions using In Situ Cell 
Death Detection Kit, Fluorescein (Roche, Mannheim, Germany). 
3.8.2 Annexin V-PI staining 
Frequencies of living and apoptotic cells of the thyroid explants were analyzed by an 
Apoptosis detection kit (Annexin V Apoptosis Detection Kit APC, eBioscience, San Diego, 
CA, USA). Brieﬂy, thyroid explants were freshly harvested and digested with 1 mg/ml 
collagenase/dispase and 2 ug/ml DNase I (Roche Diagnostics, Switzerland) at 370 C for 20 
minutes until single cell suspension was obtained. Cells were washed once in 1x binding 
buffer and were incubated for 15 min at RT with AnnexinV-APC. Cells were once again 
washed in 1x binding buffer and 5ul propidium iodide (PI) was added. Immediately cells were 
analyzed on BD FACSAria II ﬂow cytometer (Becton Dickinson, Mountain View, CA, USA). 
Annexin V - positive/PI – negative cells were considered apoptotic, whereas annexin V - 
positive/PI - positive cells were considered (late apoptotic) necrotic cells. 
 
3.9 Cell proliferation analysis with 
Bromodeoxyuridine  
In vivo proliferations of embryonic and adult thyroid tissues and ex vivo proliferation of 
thyroid explants were performed using Bromodeoxyuridine (BrdU). In vivo BrdU labeling of 
mice was done by intraperitoneal (i.p.) injection of BrdU (BD Pharmingen; 1 mg/100 ul of 
PBS per mouse) for 2 h prior to tissue isolation. Ex vivo BrdU labeling of thyroid explants 
was done by adding BrdU (BD Pharmingen; ﬁnal concentration of 10uM) for 2 h before 
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analysis. After digestion, ﬁxation and permeabilization of the tissues/ explants as described 
before, these were further treated with 30ug of DNase I (BD Pharmingen) followed by anti-
BrdU (BD Pharmingen) and 7-AAD (7-Aminoactinomycin D, BD Biosciences) staining. 
Cells were acquired immediately on BD FACSAria II ﬂow cytometer. 
3.10 Statistical analysis 
All values are depicted as mean ± SD. Data represents at least 3 independent experiments. 
Differences in means between two groups were evaluated with unpaired 2-tailed Student t 
tests. For multiple group comparisons one-way ANOVA with Tukey’s multiple comparison 
posttest was performed using GraphPad Prism version 5 for Mac OS X (GraphPad Software, 
San Diego California USA, www.graphpad.com). p values <0.05 were considered as 
signiﬁcant. 
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4. RESULTS  
The first part of the result is focused on the development of a new tool for thyroid research by 
using flow cytometry. This work is submitted for publication in journal ‘Thyroid’ and the 
manuscript for the same is in section 4.1. The second (4.2) and third sections (4.3) are focused 
on the role of HDACs and histone acetylation during thyroid development and are shown in 
detail in the respective sections.  
 
4.1 New tools for thyroid research: Flow cytometry 
of the thyroid gland 
Introductory notes 
Thyroid is a heterogeneous organ whose parenchyma is composed of epithelial cells, 
endothelial cells, and fibroblasts. These data are based on immunohistochemical studies of the 
entire thyroid gland within the embryo. However, thyroid research is limited by the lack of a 
robust tool to identify and analyze the distinct cell types of the heterogenous organ separately. 
So far, flow cytometry is not established in the field.  
 
To overcome this limitation and to analyze the role of histone acetylation in each cell type 
separately, we developed first a unique a robust flow cytometry protocol for identification of 
the distinct cell types and second, a protocol to quantify epigenetic changes for the embryonic 
as well as adult thyroid gland.   
 
Flow cytometry protocol for the identification and quantification of distinct cell types in 
embryonic and adult thyroid is presented in a format as the submitted manuscript. Role of 
HDACs and of histone acetylation for the regulation of normal thyroid development is 
presented in section 4.2 and 4.3, see below.  
 
Contribution 
The work described below is submitted for publication in the Thyroid journal. The manuscript 
ID is THY-2015-0523. My contribution to this work was to establish the whole flow 
cytometry protocol for the identification and quantification of the discrete cell populations as 
well as establish protocol to study proliferation in these cells. I was responsible for the 
dissection of embryonic and adult thyroids from mice, for preparing single cell suspensions 
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from these heterogeneous murine thyroid tissues, for the labeling these cells with cell-type 
anti-mouse specific antibodies, for the acquisition of the cells on flow cytometer and the 
analysis of the data. These contributions were considered significant and I was acknowledged 
as first author of the work.  
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4.2 Epigenetic changes during thyroid development 
in vivo. 
In a first line of research, we decided to investigate the possible epigenetic changes associated 
with histone acetylation during thyroid development in vivo at three levels. We analyzed, 
whether HDAC expression, HDAC activity and histone acetylation was dynamically changed 
during thyroid development.  
4.2.1 General HDAC activity 
In order to investigate the changes in HDAC activity during mouse thyroid development, total 
HDAC activity assay was carried out in TFC precursors (E13.5), in differentiating TFCs 
(E15.5), and in adult TFCs. Total HDAC activity decreased by 28% from E13.5 to E15.5 
developmental stage and by 60% between E13.5 and adult stage (Figure 10).  
 
	
	
 
4.2.2 Expression of HDAC1 and HDAC2 
The histone deacetylases HDAC1 and HDAC2 play a very important role in developmental 
processes and exhibit developmental stage and lineage-specific expression patterns. To 
examine the individual contribution of these deacetylases during thyroid development, we 
measured the expression levels of HDAC1 and HDAC2 using flow cytometry at E13.5, 
E15.5, E17.5 and adult thyroid.  Cells were first labeled with antibodies for respective cell 
type: anti-EpCAM for epithelial cells, anti-PECAM for endothelial cells and anti-PDGFRa for 
fibroblasts and later labeled with HDAC1 or HDAC2. Differences in the levels of HDACs in 
total thyroid cells, and in epithelial cells, endothelial cells and fibroblasts at E13.5, E15.5, 
Figure 10. HDAC activity at different stages of TFC differentiation. 
Total HDAC enzymatic activity was measured from E13.5 (set to 100%) 
to adult thyroids. Each column represents triplicates of n=16 pooled 
embryonic thyroids at E13.5 and E15.5, and n= 3 at adult stage. RFU, 
Reference Fluorescence Units. Bar diagrams display the mean, SD and 
one-way ANOVA with Tukey’s Multiple Comparison post test (*P < 
0.05, **P < 0.01, ***P< 0.001, n = 3). 
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E17.5 and adult thyroid are shown in a representative Figure 11A for HDAC1 and Figure 12A 
for HDAC2. For quantification, HDAC levels were measured as geometric mean fluorescence 
units (MFIs).  
The level of HDAC1 in total thyroid cells was highest at E13.5 and at E15.5 (Figure 11B). 
Significant decrease by 28% was observed between E13.5 and E17.5, and further decrease by 
28% in adult thyroid. In epithelial cells, the HDAC1 levels are highest at E13.5 and in adult, 
and significant decrease by 41% was observed at E15.5 and E17.5. In endothelial cells, the 
HDAC1 levels are highest in E13.5 and significant decrease by 23% was observed at E15.5, 
further decrease by 30% at E17.5. Fibroblasts had highest HDAC1 levels at E13.5 and at 
E15.5, and significant decrease by 26% is observed at E17.5. No change was observed 
between E17.5 and adult thyroid.  
 
	
	
 
 
 
 
 
 
 
Figure 11. Chromatin flow cytometry quantitates HDAC1 levels in developing and adult thyroid. A flow 
cytometry plot representation of HDAC1 levels in E13.5 (red peak), E15.5 (blue peak), E17.5 (green peak) and 
in adult thyroid (orange peak) after immunofluoroscently staining various thyroid cell types with HDAC1 
antibody (A). Geometric mean florescence intensity (MFI) of HDAC1 in total thyroid cells, epithelial cells, 
endothelial cells and fibroblasts of E13.5, E15.5, E17.5 and adult thyroid (B). Bar diagrams display the mean, 
SD and one-way ANOVA with Tukey’s Multiple Comparison post test (*P < 0.05, **P < 0.01, ***P< 0.001, n 
=3). 
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The level of HDAC2 in total thyroid cells was highest at E13.5 and significant decrease by 
53% was observed at E15.5 and further decrease by 43% at E17.5 (Figure 12B). In epithelial 
cells, the HDAC2 levels are highest in E13.5 and significant decrease by 38% was observed 
at E15.5. In endothelial cells, the HDAC2 levels are highest at E13.5 and at E15.5, and 
significant decrease by 45% was observed at E17.5, and further significant decrease by 51% 
in adult thyroid. Fibroblasts have highest HDAC2 levels at E13.5 and significant decrease by 
53% was observed at E15.5, and further significant decrease by 41% at E17.5. No change is 
observed between E17.5 and adult thyroid. 
 
Thus, HDAC1 and HDAC2 levels shown dynamic pattern during mouse thyroid development 
and can be measured with flow cytometry.  
 
 
Figure 12. Chromatin flow cytometry quantitates HDAC2 levels in developing and adult thyroid. A flow 
cytometry plot representation of HDAC2 levels in E13.5 (red peak), E15.5 (blue peak), E17.5 (green peak) and 
in adult thyroid (orange peak) after immunofluoroscently staining various thyroid cell types with HDAC2 
antibody (A). Geometric mean florescence intensity (MFI) of HDAC2 in total thyroid cells, epithelial cells, 
endothelial cells and fibroblasts of E13.5, E15.5, E17.5 and adult thyroid (B). Bar diagrams display the mean, 
SD and one-way ANOVA with Tukey’s Multiple Comparison post test (*P < 0.05, **P < 0.01, ***P< 0.001, n 
= 3) 
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4.2.3 Expression of H3K9acetylation 
Since the acetylation state of histones modulates chromatin structure and epigenetically 
regulates gene expression, we first checked the levels of histone H3K9ac in mouse thyroid by 
flow cytometry.  
Cells were first labeled with antibodies for respective cell type: anti-EpCAM for epithelial 
cells, anti-PECAM for endothelial cells and anti-PDGFRa for fibroblasts and later labeled 
with H3K9ac. Differences in the levels of H3K9ac in total thyroid cells, and in epithelial 
cells, endothelial cells and fibroblasts at E13.5, E15.5, E17.5 and adult thyroid are shown in a 
representative Figure 13A. For quantification, H3K9ac levels obtained in adult were kept as 1 
and fold change to adult was calculated as shown for E13.5, E15.5 and E17.5 (Figure 13B). 
The level of H3K9ac in total thyroid cells was increased by 5-fold at E13.5 and E15.5, and 
3.5-fold at E17.5. In epithelial cells, 2.5-fold increase was observed at E13.5, and 1.5-fold at 
E15.5 and at E17.5. In endothelial cells, 4-fold increase was observed at E13.5, E15.5 and at 
E17.5. In fibroblasts, 5-fold increase was observed at E13.5, E15.5 and 3-fold at E17.5. In 
aggregate, acetylation of histone H3K9 shows dynamic pattern in different cell types at 
various developmental stages during mouse thyroid development. 
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Figure 13. Chromatin flow cytometry quantitates histone H3K9ac levels in developing and adult thyroid. 
A flow cytometry plot representation of H3K9ac levels in E13.5 (red peak), E15.5 (blue peak), E17.5 (green 
peak) and in adult thyroid (orange peak) after immunofluoroscently staining various thyroid cell types with 
H3K9ac antibody (A). Geometric mean florescence intensity (MFI) of H3K9ac in total thyroid cells, epithelial 
cells, endothelial cells and fibroblasts was calculated and the MFI of adult thyroid was set to 1, as indicated by 
dotted line, and the fold response to adult was calculated. Bar diagrams display the mean, SD and one-way 
ANOVA with Tukey’s Multiple Comparison post test (*P < 0.05, **P < 0.01, ***P< 0.001, n = 3). 
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4.3 Effect of HDAC inhibition on thyroid 
development ex vivo. 
In a second line of research, we decided to modify HDAC activity pharmacologically in an ex 
vivo culture model of the developing thyroid and to analyze the effect of HDAC inhibition on 
key steps of thyroid development.  
4.3.1 Effect of HDAC inhibition on epigenetic markers 
To quantify the effect of HDAC inhibition on epigenetic parameters, we chose to quantify; 1) 
changes in total HDAC enzymatic activity, 2) changes in acetylation of a specific histone 
mark H3K9 by immunohistochemistry and flow cytometry, and 3) to provide evidence of 
change at H3K9 by HDACi, we were able to quantify for the first time by flow cytometry the 
epigenetic switch from methylated to acetylated state at H3K9. 
General HDAC activity in our ex vivo culture model 
In order to validate our ex vivo culture model for epigenetic research, we investigated the 
changes in HDAC activity in our ex vivo model during mouse thyroid development. Total 
HDAC activity assay was carried out in TFC precursors (E13.5), in differentiating TFCs 
(E13.5 + 3d), and in adult thyroids (Adult + 7d). Total HDAC activity decreased by 40% from 
E13.5 to E13.5 + 3d developmental stage and by 80% between E13.5 and adult thyroid 
(Figure 14). These results provided evidence that developmental changes of total HDAC 
activity in our culture model recapitulated HDAC activity levels in vivo (Figure 10). 
 
 
Figure 14. HDAC activity measured ex vivo. Total HDAC enzymatic activity was 
measured at E13.5 (set to 100%), at E13.5 +3d and at Adult +7d stages. Each column 
represents triplicates of n=16 pooled embryonic thyroids at E13.5 and at E13.5 + 3d, 
and n= 3 at adult stage. RFU, Reference Fluorescence Units. Bar diagrams display the 
mean, SD and one-way ANOVA with Tukey’s Multiple Comparison post test (*P < 
0.05, **P < 0.01, ***P< 0.001, n = 3). 
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General HDAC activity after HDAC inhibition 
 
In order to investigate the changes in HDAC activity in our ex vivo model after HDACi 
during mouse thyroid development, total HDAC activity assay was carried out in E13.5 + 3d 
thyroid explants without any treatment (Control), and with HDAC inhibitors VPA 1mM and 
TSA 5uM, and with HATi Curcumin 10uM. Total HDAC activity decreased by 50% after 
HDACi by VPA and TSA and no change was observed after HATi by curcumin as expected 
(Figure 15). Thus, pharmacological modulation of HDAC activity by VPA and TSA was 
effective in our model. 
 
 
 
H3K9acetylation/trimethylation after HDAC inhibition  
To investigate whether an epigenetic switch occurs in a spatiotemporal manner between two 
histone marks on the same specific residue, one mark that is usually associated with gene 
activation and other usually with gene repression, we first measured the pattern of H3K9ac 
(mark for gene activation) and H3K9me3 (mark for gene repression) by 
immunohistochemistry. E13.5 thyroids were cultured for 3 days and 7 days, without (control) 
and with HDACi (VPA 1mM), and were immunostained for H3K9 acetyl or H3K9 tri-methyl 
histone marks (Figure 16A- 16D). The fluorescence intensity for H3K9ac after 3 days of 
culture in control was higher in the periphery than in the center whereas in VPA 1mM treated 
explants, it was heterogenous throughout the explant (Figure 16A). After 7 days of culture, 
fluorescence intensity for H3K9ac was higher throughout the VPA 1mM treated explants than 
in control (Figure 16B). The fluorescence intensity for H3K9me3 after 3 days of culture in 
control was higher in the center than in the periphery whereas it was higher in the periphery in 
VPA 1mM treated explants (Figure 16C). After 7 days of culture, fluorescence intensity for 
Figure 15. HDAC activity measured ex vivo after HDACi. Total HDAC 
enzymatic activity was measured at E13.5 +3d, control (set to 100%), and 
after treatment with HDACi VPA 1mM and TSA 5uM, and HATi 
Curcumin 10uM. Each column represents triplicates of n=16 pooled 
embryonic thyroids at E13.5 and at E13.5 + 3d, and n= 3 at adult stage. 
RFU, Reference Fluorescence Units. Bar diagrams display the mean, SD 
and one-way ANOVA with Tukey’s Multiple Comparison post test (*P < 
0.05, **P < 0.01, ***P< 0.001, n = 1). 
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H3K9me3 was higher throughout the VPA 1mM treated explant and was higher in the 
periphery in the control explant (Figure 16D). In summary, an inverse spatial distribution of 
H3K9ac vs. H3K9me3 was observed in control tissues at day 3 and day 7. In VPA treated 
tissues, no clear pattern was detected.  
 
 
 
Next, as observed spatial labeling patterns of H3K9ac and H3K9me3 did not provide detailed 
information on changes in individual cell types after HDAC inhibition, we then quantified the 
levels of acetylation (H3K9ac) and tri-methylation (H3K9me3) at H3K9 residue by flow 
cytometry in all thyroid cells as well as in each individual thyroid cell populations. Cells were 
first labeled with antibodies for respective cell type: anti-EpCAM for epithelial cells, anti-
PECAM for endothelial cells and anti-PDGFRa for fibroblasts and later labeled with H3K9ac. 
Figure 16. H3K9 acetylation and H3K9 tri-methylation after HDAC inhibition ex vivo. OCT embedded 
thyroid cultures with and without VPA 1mM treatment for 3 days (Figure A and C) and 7 days (Figure B and D) 
were cut in sections and analyzed by immunofluorescence microscope (A-D). Sections were stained for Dapi 
(blue), H3K9ac (red) (A-B) and H3K9me3 (red) (C-D) Scale bar = 100 uM.  
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Differences in the levels of H3K9ac in epithelial cells, endothelial cells, fibroblasts, and total 
thyroid cells and at E13.5+3d are shown in a representative Figure 17A. H3K9ac levels 
obtained after HDACi in control explants are kept at 1 and fold change from control are 
calculated. Significant changes were observed in the levels of H3K9ac after 3 days of culture 
(Figure 17B). 2-fold increase in H3K9ac levels was observed on HDACi in total thyroid cells, 
epithelial cells, endothelial cells and fibroblasts respectively.  Significant 1.5-fold increase in 
H3K9ac levels was observed in epithelial cells and total thyroid cells after 7 days of culture 
(Figure 17C). This suggested that HDAC inhibition caused increased H3K9 acetylation in all 
cell types after 3 days. This effect was only maintained over 7 days in epithelial cells. 
 
Figure 17. Flow cytometry changes in H3K9 acetylation after HDAC inhibition ex vivo. A representative 
flow cytometry plot of H3K9ac levels in control (red peak) and with VPA 1mM treatment (blue peak) after 3 
days of culture (A). Changes in H3K9ac levels in control and VPA 1mM treated explants as measured by flow 
cytometry after immunofluoroscently staining with H3K9ac antibody after 3 days (B) and 7 days (C). Geometric 
mean florescence intensity (MFI) of H3K9ac in each cell type was calculated and the MFI of control was set to 
1, as indicated by dotted line, and the fold response to VPA was calculated. Bar diagrams display the mean, SD 
and t test statistics (*P < 0.05, **P < 0.01, ***P< 0.001, unpaired t test, n = at least 3).  
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To observe an epigenetic switch, H3K9ac and H3K9me3 levels obtained after 3 days of 
culture were further measured in HDACi treated and non treated  (control) explants and their 
MFI was calculated. Levels in control explants are kept at 1 and fold change from control are 
calculated. Significant changes were observed in the levels of H3K9ac and H3K9me3 (Figure 
18). 2 fold increase in H3K9ac and 0.5 fold decrease in H3K9me3 was observed in total 
thyroid cells, endothelial cells and fibroblasts respectively, whereas in epithelial cells, 
significant 2 fold increase was seen in H3K9ac and no significant change was seen in 
H3K9me3 levels. Thus an epigenetic switch occurred at histone H3K9 residue on HDACi 
between the transcription activating mark (H3K9ac) and transcription repressive mark 
(H3K9me3). 
 
 
 
4.3.2 Effect of HDAC inhibition on thyroid development 
After having provided proof of significant changes of HDAC activity and as a consequence an 
increased level of H3K9 acetylation associated with concomitant decrease in H3K9 tri-
methylation, we analyzed the effect of the disordered histone code on thyroid development. 
To do so we analyzed the effect of HDACi on folliculogenesis, angiogenesis, proliferation 
and gene expression.  
 
Figure 18. Epigenetic switch at H3K9 residue as analyzed by flow 
cytometry. Changes in H3K9ac and H3K9me3 levels in control and 
VPA 1mM treated cultures as measured by FACS after 3 days. 
Geometric mean florescence intensity (MFI) of H3K9ac or H3K9me3 
in each cell type was calculated and the MFI of control was set to 1, 
as indicated by dotted line, and the fold response to VPA was 
calculated. Bar diagrams display the mean, SD and t test statistics (*P 
< 0.05, **P < 0.01, ***P< 0.001, unpaired t test, n = at least 3).  
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HDACi treatment suppresses follicle formation  
We first analyzed the effect of HDAC inhibition during mouse thyroid development with 
HDAC inhibitor Valproic acid (VPA) on the formation of thyroid follicles. Thyroid follicle is 
the functional unit of thyroid gland and proper formation of thyroid follicle is one of the final 
key steps of thyroid development and lack of follicles is a hallmark of TD. E13.5 thyroids 
were cultured on floating filters at the air-medium interface for 3 and 7 days. Under control 
conditions, the TFCs start to form thyroid follicles after 3 days and complete follicle 
formation occurs after 7 days, thus replicating the thyroid development process in vivo.  
Effect of HDACi on structural differentiation of these explants was analyzed in presence and 
absence (control) of increasing dose of VPA from 0.5 mM to 1.5 mM.  
First, hematoxylin/eosin staining of the explants revealed that in the absence of VPA 
treatment, thyroid follicles start to form at day 3 (Figure 19A, shown with an arrow) and 
folliculogenesis with enlargement of the follicle surface is ongoing at day 7 of culture (whole 
process of folliculogenesis was completed by day 7) (Figure 19B, shown with an arrow). In 
contrast, with VPA treatment, drastic clear decrease in follicle number and follicle surface 
formation was observed at day 3 and day 7 (Figure 19A and 19B).  
Secondly, morphometric analyses of HE stained sections was done to quantify 1) the total 
number of follicles per section and 2) - to compensate for decreased tissue size after VPA 
treatment - the total follicle surface per tissue surface for each treatment condition. Significant 
dose dependent decrease in the total number of follicles formed (day 3 and 7) as well as the 
total follicle surface per tissue surface (day 7) was observed after HDAC inhibition by VPA 
(Figures 19C and 19D, and Table 3). Thus, HDAC inhibition by VPA inhibited follicle 
formation.  
Table 3. Total follicle surface at E13.5+7 in control and VPA treated thyroids. Results 
represent analysis of 10 tissues for each condition *** P<0.001                                
Mean follicle surface 
/tissue surface (um2/um2) 
Control VPA 
0.5mM 
VPA 
0.75mM 
VPA 
1.0mM 
VPA 
1.5mM 
mean 0.038 0.006 *** 0.005 *** 0.004 *** 0.002 *** 
SD 0.016 0.003 0.002 0.003 0.001 
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Morphometric analyses of surface area of the explants were done to quantify change in 
surface area after HDACi. Significant dose dependent decrease in the surface area at day 3 
was observed after HDAC inhibition by VPA (Figure 20). Thus, HDAC inhibition by VPA 
A
E13.5 + 3d
Control VPA 
VPA 0.5mM VPA 0.75mM VPA 1mM VPA 1.5mM 
Figure 19. Dose dependent decrease in follicle numbers. E13.5 mouse thyroids were cultured at the air-
medium interface for 3 and 7 days, with or without HDACi VPA. VPA was added at increasing doses from 0.5 
mM to 1.5 mM. Untreated cultures were analyzed as control tissues. Representative images of 
hematoxylin/eosin staining after 3 (A) and 7 (B) days in culture are shown. An arrow indicates a thyroid follicle 
formed at day 3 (A) and day 7 (B) in control culture. Fewer follicles were observed with VPA treatment than in 
the control at day 3 and 7. Morphometric analysis revealed dose dependent significant decrease in the total 
follicles formed after VPA treatment at day 3 (C) and 7 (D) than in the control. Scale bar, 100 um. Bar diagrams 
display the mean, SD and t test statistics. Each column represents analysis of at least 5 cultures. Each section of 
the culture was measured twice (***P< 0.001, unpaired t test, n = 3). 
B
E13.5 + 7d
Control VPA 
VPA 0.5mM VPA 0.75mM VPA 1mM VPA 1.5mM 
C D
E13.5 + 3d E13.5 + 7d
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suggested disturbed growth of the explants. Since we observed smaller explant surface by 
hematoxylin and eosin stain, we quantified the difference in surface area between control and 
the four applied VPA doses.  
Figure 20. Dose dependent decrease in surface area of the 
explants. E13.5 mouse thyroids were cultured at the air-medium 
interface for 7 days, with or without HDACi VPA. VPA was added at 
increasing doses from 0.5 mM to 1.5 mM. Untreated explants were 
analyzed as control tissues. Morphometric analysis revealed dose 
dependent significant decrease in the explant surface area formed after 
VPA treatment at day 3 than in the control. Bar diagrams display the 
mean, SD and t test statistics. Each column represents analysis of at 
least 5 explants. Each section of the explant was measured twice 
(***P< 0.001, unpaired t test, n = 3). 
 
 
 
 
 
HDACi disturbs angiogenesis 
To assess whether HDACi has an effect on angiogenesis during thyroid development, E13.5 
thyroids were cultured for 3 and 7 days, without (control) and with (VPA 1mM). Explants 
were then immunostained with endothelial cell specific antibody anti-PECAM and thyrocyte 
specific antibody anti-NKX2-1 (Figure 21A and 21B). In control explants, abundant network 
of blood vessels surrounding the thyroid follicle was observed after 3 and 7 days of culture. 
However, decreased network of blood vessels was observed after VPA treatment after 3 and 7 
days of culture suggesting disturbance in angiogenesis in these explants.  
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HDACi treatment does not induce apoptosis 
To investigate whether apoptosis is induced after HDACi on E13.5 thyroids cultured for 3 and 
7 days, we performed Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 
assay (TUNEL) on the explants.  Using TUNEL assay, we found out that VPA treatment after 
3 and 7 days did not modify the number of apoptotic cells (Figure 22A). This was confirmed 
by performing Annexin V- Propidium iodide (PI) staining on these explants and no significant 
difference was observed in HDACi treated explants as compared to control, either after 3 or 7 
days (Figure 22B). These results show that HDACi treatment does not modify apoptosis and 
further suggests that the effects of HDACi on thyroid differentiation and development are 
direct. 
 
	
	
	
	
	
	
Figure 21. HDAC inhibition inhibits angiogenesis. OCT embedded thyroid cultures with and without VPA 
1mM treatment for 3 days (A) and 7 days (B) and analyzed by confocal microscope. Sections were stained for 
NKX2-1 (green; thyrocytes and C-cells) and PECAM (red; endothelial cells). Scale bar = 100 uM.  
Figure 22. HDACi treatment does not induce apoptosis. Immunohistochemical staining of thyroid cultures 
treated with HDACi VPA 1mM for 3 and 7 days (A). TUNEL positive cells are shown in green color and nuclei 
of all the cells were stained with Dapi, shown in blue. Scale bar = 100 uM. Annexin V – Propidium iodide (PI) 
staining by flow cytometry on the explants in column graphs (B).  
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Direct effect of HDACi on follicle formation  
So far, decreased follicle formation and angiogenesis was observed in HDACi treated tissues. 
(Figures 19 and 21, respectively). To assess whether HDACi inhibits follicle formation and 
angiogenesis both directly, or decreased follicle formation would be a consequence of 
decreased angiogenesis, we used an angiogenesis inhibitor Sunitinib. E13.5 thyroids were 
treated without (control) and with the angiogenesis inhibitor Sunitinib 1uM for 3 and 7 days.  
Explants were immunostained with endothelial cell specific antibody anti-PECAM and 
thyrocyte specific antibody anti-NKX2-1 (Figures 23A and 23B). Huge network of blood 
vessels was observed around thyroid follicles in control tissues after 3 and 7 days, however it 
was completely absent in Sunitinib treated explants. Absence of endothelial cells was also 
confirmed by performing flow cytometry on these explants as no CD31 (PECAM) positive 
cells are seen (Figures 23C and 23D). However, in spite of no angiogenesis, we still observed 
some but reduced follicle formation compared to control, suggesting that HDAC inhibition 
has direct effects on both, follicle formation and angiogenesis.  
 
 
 
 
 
 
Figure 23. Direct effect of HDACi on angiogenesis. OCT embedded thyroid explants with and without 
Sunitinib 1uM treatment at 3 (A) and 7 (B) days were cut in sections and analyzed by confocal microscope. 
Sections were stained for NKX2-1 (green; thyrocytes and C-cells) and PECAM (red; endothelial cells). Scale bar 
= 100 uM. Flow cytometry plots of thyroid explants without (control) or with Sunitinib 1uM for 3 (C) and 7 (D) 
days. 
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HDACi decreases proliferation of epithelial and endothelial cells 
To investigate the effect of HDACi on proliferation of thyroid cell populations during thyroid 
development, we analyzed BrdU incorporation by immunohistochemistry and flow 
cytometry. E13.5 thyroids cultured for 3 and 7 days, without (control) and with (VPA 1mM) 
were incorporated with BrdU for 2 hours prior to removing the explants from the culture 
conditions. Immunohistochemical staining of the explants shows few cells that are BrdU 
positive after VPA treatment as compared to control, both at 3 (Figure 24A) and 7 (Figure 
24B) days. Since, it was not able to confirm and quantify that in which cell type this 
decreased proliferation occurred, we analyzed the explants by flow cytometry. BrdU was 
incorporated into explants for 2 hours before removing them for flow cytometry analysis. 
They were labeled with antibodies for respective cell type: anti-EpCAM for epithelial cells, 
anti-PECAM for endothelial cells and anti-PDGFRa for fibroblasts, and further with anti-
BrdU and 7-AAD that marks the DNA. Cell proliferation in respective cell type, at 3 and 7 
days of culture, either without (Control) or with (VPA 1mM) is seen in representative plots 
from one of the experiment (Figure 24C and 24D).  On HDACi with VPA 1mM, significant 
reduction in absolute numbers of BrdU positive cells after 3 days of culture was observed in 
total thyroid cells (60%), epithelial cells (95%) and endothelial cells (90%) (Figure 24E). 
After 7 days of culture, significant reduction in absolute numbers of BrdU positive cells was 
observed in total thyroid cells (50%), epithelial cells (75%) and endothelial cells (97%) 
(Figure 24F), whereas no difference was observed in fibroblasts at either after 3 or 7 days of 
culture (Figure 24E and 24F).  
 
 
 
 
 
 
 
 
A
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Control VPA 
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Figure 24. Analysis of proliferation after HDACi. Immunohistochemistry for BrdU performed on control 
(untreated) and VPA 1mM treated cultures for 3 (A) and 7 (B) days. Thyroid cultures were labeled with BrdU 
for 2 hours. Scale bar = 100 uM. Cell cycle analysis of individual cell types after 2 hours BrdU labeling at day 3 
(C) and day 7 (D). Flow cytometry plots depict intracellular expression of BrdU and 7-AAD (7-
Aminoactinomycin D), which marks the DNA. The numbers represent frequencies of cells in G0/G1 (BrdU- 7-
AAD-), S (BrdU+ 7-AAD-/+) and G2/M phase (BrdU- 7-AAD+). Absolute number of BrdU positive cells obtained 
by FACS analysis after VPA 1mM treatment for 3 (E) and 7 (F) days. Bar diagrams display the mean, SD and t 
test statistics (*P < 0.05, **P < 0.01, ***P< 0.001, unpaired t test, n = at least 3). 
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HDACi decreases cellularity of epithelial and endothelial 
subpopulations of thyroid 
To investigate the effect of HDACi on thyroid cell populations during thyroid development, 
we analyzed the total thyroid cellularity as well as individual thyroid cell populations by flow 
cytometry. E13.5 thyroids after 3 and 7 days of culture, without (control) and with (VPA 
1mM) were labeled with antibodies for respective cell type: anti-EpCAM for epithelial cells, 
anti-PECAM for endothelial cells and anti-PDGFRa for fibroblasts (Figure 25A and 25C). On 
HDACi with VPA 1mM, total and individual cell type specific cellularity in absolute numbers 
did not change significantly after 3 days (Figure 25B), however significant decrease was 
observed after 7 days in total thyroid cells (60%), epithelial cells (50%) and endothelial cells 
(80%), whereas no difference was observed in fibroblast population (Figure 25D). After both, 
3 and 7 days of culture in either presence or absence of VPA, fibroblasts were the major 
population followed by epithelial cells and the smallest were endothelial cells. Thus, HDACi 
treatment caused decrease in total thyroid cells, epithelial cells and endothelial cells after 7 
days of culture, whereas fibroblast population remained unchanged. In summary, HDACi 
caused decreased endocrine cell mass, a phenotype reminiscent of thyroid hypoplasia in 
patients with TD. 
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HDACi alters thyroid specific gene expression 
Besides structural differentiation of an organ, its function is dependent on proper gene 
expression of tissue specific set of functional gene. Expression of genes involved in thyroid 
development, such as Pax8, genes encoding proteins involved in thyroid hormone synthesis 
such as Nis, Tg, Tpo, and genes encoding cell adhesion molecules involved in folliculogenesis 
and angiogenesis such as Cdh16, Pecam and EpCAM, was done by using real-time PCR. 
After 3 days of culture with HDACi VPA 1mM, expression of Pax8 was increased, whereas 
expression of Nis, Tpo and Cdh16 is significantly decreased. No significant changes are seen 
in the expression of Tg, Pecam and EpCAM (Figure 26A). After 7 days of culture with 
HDACi VPA 1mM, expression of functional genes such as Nis, Tg and Tpo was significantly 
increased, whereas expression of Cdh16 and Pecam was significantly decreased (Figure 26B). 
Thus HDAC inhibition profoundly altered gene expression during thyroid development. 
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Figure 25. Analysis of cellularity after HDACi. Flow cytometry plots of thyroid cultures after HDACi of all 
epithelial cells (EpCAM+), endothelial cells (PECAM+) and fibroblasts (PDGFRa+) are indicated in zebra plots 
for 3 (A) and 7 (C) days. Comparative cellularity of epithelial, endothelial, fibroblasts and total thyroid 
cellularity after 3 (B) and 7 (D) days of VPA treatment. Each column represents pool of at least 10 thyroids (*P 
< 0.05, **P < 0.01, *** P< 0.001, unpaired t test, n = 3).  
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Figure 26. Thyroid specific gene expression after HDACi. Real time PCR quantification of Pax8, Nis, Tg, 
Tpo, Cdh16, Pecam and EpCam after 3 (A) and 7 (B) days of HDACi with VPA 1mM. Values obtained from 
control are set to 1 as shown in the dotted line and mRNA fold change to VPA 1mM was calculated. Bar 
diagrams display the mean, SD and t test statistics (*P < 0.05, unpaired t test, n = at least 3). 
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5. DISCUSSION 
Focusing on molecular mechanisms of normal and abnormal thyroid development, this work 
had two main aims: 
First, to establish a flow cytometry protocol for the thyroid gland and provide a new research 
tool for detailed quantification of the different cell populations and their growth dynamics 
during normal murine thyroid development, and in murine models of thyroid disease. 
Second, to investigate the role of HDACs and of histone acetylation for regulation of thyroid 
development and to investigate whether disordered histone acetylation might cause disturbed 
thyroid development reminiscent of thyroid dysgenesis in patients with congenital 
hypothyroidism.   
 
5.1. Cell growth dynamics in embryonic and adult mouse 
thyroid revealed by a novel approach to detect thyroid 
gland subpopulations 
 
The thyroid is composed of endocrine epithelial cells, blood vessels and mesenchyme. 
Fluorescence-activated cell sorting (FACS) provides a tool for quantification of distinct cell 
populations. However, flow cytometry has not been a standard protocol up to this date for 
thyroid research. Thus, in the absence of an established tissue-specific protocol, no data exist 
on absolute cell numbers, relative distribution, and proliferation of the different cell 
populations in the developing and mature thyroid. The aim of this study was to establish a 
flow cytometry protocol allowing quantification of cell populations in murine embryonic 
(E13.5, E15.5, and E17.5) and adult thyroid tissues. These time points were chosen as 
structural and functional differentiation of TFCs occurs between E14.5-E16.5. Structural 
differentiation is characterized by follicle formation, angiogenesis and growth of the tissue. 
Functional differentiation is characterized by onset of thyroid hormone synthesis. Thus, if 
reliable, a flow cytometry protocol should detect major changes in absolute cell number and 
relative frequency of cell populations during this time window of morphogenesis and 
differentiation. 
 
A gating strategy and the use of antibodies for flow cytometry were established allowing 
characterization of TFCs and C-cells (EpCam+/Nkx2-1+ cells), parathyroid cells 
(EpCam+/Nkx2-1- cells), endothelial cells (Pecam+ cells), fibroblasts (PDGFRa+ cells) after 
 
 
96 
exclusion of Ter119+ erythrocytes and CD45+ hematopoietic cells. Specificity of antibodies 
was validated whenever available by a second cell type specific marker: epithelial cells 
(EpCam, E-cadherin, Nkx2-1) and endothelial cells (Pecam, Icam-1).  
For the first time, our study provided quantitative data on the absolute parenchymal cell 
number per thyroid (mean±SD): it increased from 7300±1300 at E13.5 to 190000±20000 in 
adult tissues. As expected, Nkx2-1+ cells represented the largest cell population in adult 
tissues. Surprisingly, at all three embryonic stages thyrocytes accounted only for a small 
percentage of the total thyroid cell mass. In contrast, the largest cell population at all three 
embryonic stages were PDGFRa+ fibroblasts, while representing the smallest cell population 
in adult tissues. Pecam+ endothelial cells increased significantly from E13.5 to E15.5 and 
remained stable at E17.5 and adult tissues.   
Proliferation rate was significantly different between embryonic cell populations with distinct 
proliferative peaks at E13.5 in epithelial cells and at E15.5 in endothelial cells (22±2% 
BrdU+), while fibroblasts showed a constant proliferation rate in embryonic tissues. In adult 
tissues, BrdU+ cells were below 1% in all cell types. 
Finally, an unknown cell population was revealed by our gating strategy that was found to be 
Nkx2-1-/CD45-/Pecam-/PDGFRa-/EpCam-/Ter119- negative. From histological studies, such a 
cell population is not evident. So a detailed characterization by transcriptome analysis and use 
of further surface markers, e.g. stem cell markers, could provide more insight into the origin 
and putative role of this yet unknown cell population.  
 
In summary, we established a flow cytometry protocol for quantification of developmental 
dynamics in thyroid cell populations providing a new tool for functional analysis in murine 
thyroid disease models. The detailed discussion is mentioned in the manuscript (Section 
4.1.4). The flow cytometry protocol was the basis for detailed investigation on epigenetic 
regulation of thyroid development - the second main aim of this thesis. For this, the gating 
strategy was adapted and extended to allow cell type specific quantification of changes at 
distinct epigenetic histone marks (H3K9ac, H3K9me3), as detailed in the results section and 
discussed below. 
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5.2. Epigenetic regulation of thyroid development: A new 
hypothesis 
 
The three main arguments from clinics and biology suggesting epigenetic cause of TD are: 
1. High discordance rate (92%) for TD between monozygotic twins and the sporadic 
occurrence of TD due to non-Mendelian inheritance pattern in majority of the cases (98%).  
2. Loss of histone acetylation during thyroid carcinogenesis being associated with loss of 
structural and functional differentiation marker of TFCs.  
3. Inhibition of HDAC activity during development of pancreas, intestine and kidney caused 
abnormal organogenesis and differentiation.  
 
The developing human thyroid undergoes a series of complex changes during embryogenesis 
to become functional at the end of the first trimester as summarized in Table 1 in the 
introduction. Developmental defects at any stage might lead to TD. TD is the most prevalent 
form of CH representing 85% of all cases and is mainly a sporadic disorder associated with a 
non-Mendelian inheritance pattern.  Only 2% of TD cases are familial (Castanet et al., 2000). 
Further, the key argument for an epigenetic cause of TD is the observation that monozygotic 
twins - thus genetically identical individuals - exhibit a high discordance rate (92%) for TD 
(Perry et al., 2002). This suggests post zygotic and thus somatic mutations or epigenetic 
mechanisms being involved in TD (Vassart & Dumont, 2005; Deladoëy et al., 2007). Finally, 
monogenetic forms of TD caused by mutations in thyroid enriched transcription factors  
(PAX8, NKX2-1, FOXE1, TSHR) that regulate thyroid development, are found in only 5% of 
the TD cases in large cohorts (De Felice and Di Lauro, 2004; Szinnai, 2014). The cause in the 
remaining cases still remains unknown. In summary, the hypothesis of epigenetic rather than 
monogenetic cause of TD is supported by clinical and genetic data in different cohorts of 
patients with TD.  
 
Epigenetic changes also play an important role in thyroid tumourigenesis affecting 
differentiation and proliferation. Epigenetic silencing due to loss of histone acetylation is 
associated with loss of differentiation markers of TFCs such as TPO, NIS, Tg and TSHR 
(Russo et al., 2011). Redifferentiation of the TFCs with HDACi to restore NIS expression and 
make thyroid tumors radioiodine sensitive has become a new therapeutic goal in treatment of 
thyroid cancer (Kogai et al., 2006). Cooperative effects of suberoylanilide hydroxamic acid 
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(SAHA) and VPA on BCPAP, a papillary thyroid carcinoma derived cell line, and FRO, an 
anaplastic thyroid carcinoma cell line, was observed on NIS gene expression (Puppin et al., 
2012). HDACi VPA, TSA and depsipeptide have been shown to restore NIS expression at 
mRNA and protein level in papillary, follicular, and anaplastic cell lines, while iodide uptake 
in papillary and anaplastic thyroid cancer cell lines have only been shown for VPA and 
depsipeptide (Kitanzono 2001, Fortunati 2004, Furuya, 2004). New HDACi Belinostat, 
Panobinostat and classical HDACi VPA have been shown to induce apoptosis and cell cycle 
arrest in poorly differentiated thyroid carcinoma cell lines (Chan et al., 2013; Catalano et al., 
2005). Also, over-expression of proteins with HAT activity (pCAF and p300) in HeLa cells 
resulted in stimulation of the NIS promoter (Puppin et al., 2005). These findings strongly 
suggest a putative role of histone acetylation, and more specifically the balance between 
HDACs and HATs for differentiation and de-differentiation in TFCs. 
 
Epigenetic changes due to histone modifications have recently been shown to play crucial 
roles in the transcriptional regulation of most eukaryotic genes during organ development and 
have been linked to control cell differentiation in cardiac (Backs & Olson, 2006) and muscle 
cells (McKinsey et al., 2001). Studies in early mouse embryonic reprogramming events such 
as during oocyte maturation have shown dynamic changes of specific histone modifications 
during early murine development (Sarmento et al., 2004). Histone modifying enzymes HATs 
and HDACs play an important role in developmental processes and their deregulation has 
been linked to various congenital diseases. During development, HDACs regulate directly or 
indirectly the timing of coordinated cellular differentiation in several cell types (e.g. pancreas, 
intestine, kidney)(Haumaitre et al., 2008, Tou et al., 2005, Chen et al., 2011). HDAC1 
knockout mice show proliferative defects (Lagger et al., 2002). HDAC2 knockout mice show 
cardiac malformations (Trivedi et al., 2007). These studies reveal that HDACs play a key role 
for development of distinct cell types and are not functionally redundant. 
 
In summary, all these data from human genetics, thyroid cancer and developmental biology 
suggest a putative regulatory role of epigenetic mechanisms, such as histone acetylation, for 
thyroid development. However, very few studies have investigated how thyroid development 
is regulated at the epigenetic level. The first study to hint the involvement of epigenetics in 
thyroid differentiation was on canine thyroid cell culture. Treatment of these cells with 12-O-
tetradecanoylphorbol-13-acetate (TPA) or EGF completely decreased the expression of 
specialized thyroid genes (Tg and Tpo) (Dumont et al., 1992).  On treatment with TSH or 
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with any agent that enhanced cAMP accumulation, these cells again fully expressed their 
specialized genes. Thus, on treatment with TPA or EGF TFCs remained determined but lost 
their differentiation expression and recovered it later again when exposed to TSH or other 
agents causing cAMP increase. Dumont et al concluded “this suggested the involvement of 
proteins in specific thyroid cell control and of the chromatin”.  
 
Only in 2010, possible involvement of DNA methylation in the pathogenesis of TD was 
studied by Abu-Khudir et al by comparing dysgenetic thyroid tissue from TD patients with 
normal thyroid tissues (Abu-Khudir et al., 2010). However, no difference in global DNA 
methylation profiles between the dysgenetic and normal thyroid tissues was observed.  
 
Very recently, Abu- Khudir et al provided the first evidence for epigenetic regulation of 
thyroid function by identifying a tissue dependent differentially methylated region in the 
promoter of FOXE1, and showed reduced expression of this transcription factor by epigenetic 
modulation (Abu-Khudir et al., 2014).  
 
In summary, disrupted epigenetic regulation of thyroid development represents a new 
hypothesis to explain TD in patients after exclusion of the rare known monogenetic forms.  
 
5.3. HDAC expression, HDAC activity and histone 
acetylation during normal thyroid development in vivo: an 
observational approach 
In a first line of research, we aimed at describing dynamics of general HDAC activity, 
expression of HDAC1 and 2, and the level of histone acetylation during normal thyroid 
development in vivo compared to adult tissues.  
 
During in vivo thyroid development, we observed a decline in total HDAC activity in 
differentiating TFCs (E15.5), and in adult TFCs (Figure 10) compared to TFC precursors 
(E13.5). This result was in accordance with high HDAC activity at the precursor state, and 
low HDAC activity in the fully differentiated state in other organs, e.g. pancreas or kidney 
(Haumaitre et al., 2008; Chen et al., 2011), providing a first argument for a regulatory role of 
HDACs during thyroid development.  
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In a second step, we analyzed by flow cytometry the cell type specific expression levels of 
HDAC1 and 2, the major HDACs. For HDAC1, we observed a significant decline in its 
expression in all cell types from E13.5 to adult stage, except for epithelial cells, exhibiting a 
decline at E13.5 and E15.5, but reaching again levels comparable to E13.5 in the adult tissue 
(Figure 11). For HDAC2, expression levels were higher at E13.5, and showed a distinct 
decline in all three cell types (Figure 12). In summary, HDAC1 expression in endothelial cells 
and fibroblasts and HDAC2 expression in all three cell types are in analogy with data from 
intestine, pancreas and kidney. Further, the decrease in expression levels of HDAC1 and 
HDAC2 from E13.5 to adult thyroid (Figure 11 and 12) is correlated with decreased total 
HDAC enzymatic activity. Similar pattern has been observed during pancreatic differentiation 
(Haumaitre et al., 2008), adipogenesis (Yoo et al., 2006) and osteogenesis (Lee et al., 2006). 
Thus, we are able to show that HDAC1 and HDAC2 show differential expression during 
various stages of thyroid development suggesting their differential roles correlating to various 
developmental events. 
  
As explained above, histone acetylation levels at distinct stages and in different cell types are 
the result of a balance between HDAC and HAT activity. Thus, to investigate the effect of 
developmentally decreasing HDAC activity and expression, we analyzed histone acetylation 
levels in all cell types throughout thyroid development. However, we decided not to analyze 
general H3 acetylation, but acetylation at one of the well characterized histone residues, 
associated with active gene transcription if acetylated (H3K9). Surprisingly, H3K9ac levels 
were not inversely correlated with general HDAC activity or HDAC1 and 2 expressions, but 
showed a decrease over time. Several reasons could cause this unexpected result: 
First, H3K9 is only one of the several residues in the tail of histone H3 being acetylated as 
shown in Figure 7. It remains to be shown, whether general H3 acetylation or acetylation at 
the other residues (e.g. H3K4, H3K14, H3K18, H3K27) would exhibit the expected inverse 
correlation of H3K9ac to that of general HDAC activity.  
Secondly, our assumption of inverse correlation of acetylation with HDAC activity is 
simplistic. It does not consider possible developmental dynamics of general HAT activity, the 
counterpart of HDAC activity (Figure 8). Thus, to understand in vivo changes of histone 
acetylation, the complex balance of both enzyme groups modifying histone acetylation needs 
to be analyzed. Nevertheless, these data provide evidence that acetylation of histone H3K9 
shows dynamic pattern in different cell types at various developmental stages during mouse 
thyroid development. 
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In summary, this first line of research during in vivo development of the thyroid provided 
arguments for dynamic stage dependent changes of general HDAC activity, of HDAC 
expression and of histone acetylation. However, with this first set of experiments performed, 
it was not possible to encompass the global complexity of developmentally regulated 
dynamics in histone acetylation in the physiological in vivo situation. More and more complex 
experiments such as ChIP-Seq with HDACs and histone marks are underway to get a more 
general insight into the complexity of the acetylome during thyroid development.  
 
5.4. HDAC inhibition efficiently modified histone 
acetylation in ex vivo cultured thyroids 
In a second line of research, we decided to study the role of HDACs and histone acetylation 
for thyroid development in a more controlled ex vivo system after pharmacological HDAC 
inhibition, being aware that data gathered would be more discriminative than in vivo, but the 
biological relationships simpler than during physiological, not perturbed thyroid 
differentiation. 
 
In a first set of experiments, we investigated and quantified the changes of epigenetic 
parameters in control and HDACi exposed thyroid tissues to confirm efficacy of HDAC 
inhibition. In a second set of experiments we focused on characterization of the effects of 
perturbed histone acetylation on growth and differentiation of the ex vivo cultured thyroid 
tissues (see 5.5.)  
 
Validation of the ex vivo culture model for research on HDACs and dose finding of VPA 
 
To define the role of histone acetylation in embryonic thyroid development, we used an ex 
vivo culture model that recapitulates all key steps of structural and functional differentiation 
of the embryonic thyroid gland (unpublished data Szinnai). E13.5 thyroids when cultured for 
3 days ex vivo, exhibit the features of an E15.5 thyroid in vivo, with onset of follicle formation 
and angiogenesis. E13.5 thyroids cultured for 7 days ex vivo demonstrate onset of thyroid 
hormone synthesis as in E17.5 in vivo. 
 
In a first step, we were able to show that ex vivo cultured thyroid tissues recapitulated the 
decrease of HDAC activity in vivo at discrete stages, thus validating the model for planned 
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epigenetic research focusing on HDACs (Figures 10 and 14).   
Secondly, since most HDACs were expressed during thyroid development, we chose an 
overall HDAC inhibition strategy rather than specifically but arbitrarily inactivating each 
HDAC. We used VPA as a general HDACi of class I and class II HDACs widely used in 
epigenetic research such as in several cell lines (Chen et al., 2011; Balasubramanian et al., 
2015), and validated their use in thyroid explants, an approach similar to that used with 
intestinal explants (Tou et al., 2004) and pancreatic explants (Haumaitre et al., 2008).  
Dose titration of VPA from 0.5 mM to 1.5 mM on E13.5 thyroids cultured for 3 and 7 days 
allowed to determine an effective VPA dose (1mM). It resulted in significant decrease of 
HDAC activity and exhibited no toxic effects on explants compared to control as assessed by 
comparable levels of apoptosis by Annexin V-PI staining and by TUNEL assay. Hence, VPA 
1mM was the dose of choice throughout the study. Our data validate the use of VPA for 
potently modulating HDAC activity in thyroid explants.  
 
Effect of HDAC inhibition on histone acetylation 
 
In a next step, we aimed at determining the effect of HDAC inhibition on histone acetylation 
levels in control versus treated explants. HATs acts as transcription activators and co-
activators and are associated with gene activation (Sterner and Berger, 2000; Backs and 
Olson, 2006) and HDACs can reverse the action of HATs. This interplay between HATs and 
HDACs results in dynamic transitions in chromatin structure and hence in switches between 
permissive and repressive chromatin states (Wolffe and Hayes, 1999; Roth et al., 2001). Thus, 
HDAC inhibition is expected to perturb the balance between HATs and HDACs and 
consecutively the balance between acetylated, deacteylated and methylated state of specific 
histone residues. Histone H3K9 mark has double duty, it can turn genes ‘on’ when acetylated 
and ‘off’ when methylated. Acetylation of H3K9 is highly correlated with active promoters 
(Wang et al., 2008; Karmodiya et al., 2012), whereas tri-methylation of H3K9 is highly 
correlated with inactive promoters (Barski et al., 2007).  
 
Immunohistochemical analysis revealed an inverse labeling of H3K9ac and H3K9me3 
labeling in control tissues, while treated explants showed no differential staining pattern 
throughout the explant. However, VPA treated explants exhibited a more intense H3K9ac 
labeling as expected.  
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To get a more precise picture, H3K9ac levels were quantified in individual cell types by flow 
cytometry: HDAC inhibition caused a significant increase in H3K9ac levels in all three cell 
populations after 3 days and in epithelial cells after 7 days of culture providing evidence for 
an effective modulation of histone acetylation in treated explants. 
 
Epigenetic switch from repressive to permissive chromatin state at residue H3K9 
 
Despite the crucial importance of bivalent combinations of histone modifications, very few 
methods exist to detect these combinations, such as with the sequential-chromatin 
immunoprecipitation (sequential-ChIP) assay (Bernstein et al., 2006; Geisberg and Struhl, 
2004) or a new approach with immunoprecipitation-mass spectrometry assay (Voigt, 2012). 
However, it is impossible to identify cells with a specific bivalent combination of histone 
modifications in samples with heterogeneous cell populations, such as in tissues. This 
complexity is even further difficult to address in situations where cells having a specific 
bivalent modification in samples derived from tissues at various stages of differentiation.  
 
In order to overcome these limitations, we developed a new protocol to study bivalent histone 
modifications in cells from heterogeneous population derived from thyroid tissue at various 
developmental stages using flow cytometry. We extended the initial flow cytometry 
experiment using H3K9ac antibody alone by combining quantification of H3K9ac and 
H3K9me3 levels in the same flow cytometry experiment. By this approach, we could show an 
epigenetic switch at the histone H3 tail residue K9 with significant increase of acetylation 
with concomitant decrease in tri-methylation in the total thyroid as well as for each cell type. 
This experimental setup was, to our knowledge, not used before and provided the most 
convincing proof of a specific effect of HDAC inhibition on acetylation levels (Figure 18 and 
27). 
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In summary, our data confirmed by different approaches that HDAC inhibition in our ex vivo 
explant model significantly reduced HDAC activity and resulted in an efficient modulation of 
the balance between acetylation and methylation.  
 
5.5 HDAC inhibition caused profoundly disordered 
thyroid development  
After having provided evidence for significant changes in histone acetylation by HDAC 
inhibition in our model, the next step was to analyze the effect of modified histone acetylation 
on thyroid development. Structural and functional key steps of thyroid terminal differentiation 
are follicle formation, angiogenesis, proliferation and thyroid hormone synthesis (Shepard et 
al., 1964; De Felice and de Lauro, 2004; Szinnai et al., 2007). 
  
 
 
Figure 27. The epigenetic switch at H3K9ac. HATs- Histone acetyl transferases, HDACs- Histone 
deacetylases, HMTs- Histone methyl transferases and HDMs- Histone demethylases. Acetylated histone tails 
due to transfer of acetyl groups by HATs on H3K9 residue, represent permissive chromatin. This action is 
reversed by HDACs. On HDAC inhibition, HMTs add tri-methyl groups on deacetylated histone tails 
representing repressed chromatin. On HDAC inhibition, the balance between acetylated and trimethylated 
H3K9 is shifted to the right, as HAT activity is maintained.  
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Follicle formation 
 
The thyroid follicle is the functional unit of the thyroid. Thyroid hormone synthesis and 
storage is only possible in the follicular lumen, but not within the TFCs (Dumont et al., 1992). 
HDAC inhibition in our ex vivo model caused a significant decrease of follicle number and 
total follicle surface per tissue surface. This effect was dose dependent and follicle formation 
was almost completely blocked in the highest VPA dose tested (Table 3, Figure 19). Thus, 
these data provided evidence that disturbed balance between HDACs and HATs had major 
impact on follicle formation, the key morphogenetic step of thyroid development. Reduced 
follicle number and surface results in reduced functional endocrine surface area, ultimately 
leading to insufficient endocrine function. 
 
Angiogenesis 
  
A second condition for normal function of an endocrine organ is the presence of a capillary 
net for secretion of the synthesized hormones into the blood stream. The spherical thyroid 
follicles are surrounded by a dense capillary net, the complete structure also called 
angiofollicular unit (Dumont et al., 1992; Colin et al., 2013). VPA treated explants exhibited a 
significantly reduced capillary net compared to control in immunohistochemistry (Figure 21) 
after 3 and 7 days of culture. In conclusion, not only follicle formation but also angiogenesis 
was blocked by HDAC inhibition, resulting in a disordered formation of angiofollicular units 
in the developing thyroid. This observation is in accordance with previous data. Hick et al 
have recently shown epithelial-endothelial paracrine crosstalk for angiogenesis and follicle 
formation. According to their data, TFCs secrete VEGF-A to attract endothelial cells, which 
invade the thyroid from the periphery of the organ at E14.5 and E15.5.  Follicle formation of 
the unpolarized TFCs occurred only in close contact to invading endothelial cells, and was 
blocked by an angiogenesis inhibitor (Hick et al., 2013). 
 
Arguments for direct effect of HDAC inhibition on follicle formation 
 
However, based on this observation, it remained unclear whether HDAC inhibition had direct 
effect on angiogenesis and follicle formation, or whether decreased follicle formation was a 
consequence of impaired angiogenesis and impaired paracrine interaction between the two 
cell types (Figure 28).  
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Figure 28. Schematic representation of two possible ways of HDAC inhibition to block follicle formation. Left: 
Follicle formation is directly inhibited by HDAC inhibition. Right: Decreased follicle formation is a 
consequence of direct inhibition of angiogenesis by HDAC inhibition. 
 
To answer this question, a selective angiogenesis inhibitor (Sunitinib) was used in our explant 
model. Under these conditions, angiogenesis was completely blocked, as shown by 
immunohistochemistry and flow cytometry, despite some but reduced follicle formation 
(Figure 23). In contrast, in VPA treated explants, some but reduced angiogenesis was 
observed, but follicle formation was almost completely blocked compared to Sunitinib treated 
explants. In summary, these results are 1) in accordance with the notion that angiogenesis 
triggers follicle formation and 2) suggest that HDAC inhibition itself has a direct effect on 
follicle formation independently of reduced angiogenesis. 
 
Proliferation and growth dynamic of cell populations 
 
A direct effect of HDAC inhibition was visible by eye: VPA treated explants were smaller 
than control explants (Figure 19). This effect was dose dependent as shown in Figure 20. As 
stated above, toxic effects of VPA 1.0mM were excluded by TUNEL staining and flow 
cytometry (Figure 22). As HDAC inhibitors are known to have anti-proliferative effects 
(Mottamal et al., 2015), we investigated by immunohistochemistry as well as by flow 
cytometry using BrdU differences in proliferative rate in control versus VPA treated tissues. 
While immunohistochemistry revealed a higher number of BrdU positive cells in control 
tissues compared to HDACi treated explants, it provided no clear picture on cell specific 
proliferation rate. Quantification of absolute numbers of BrdU positive cells in each cell 
population was possible by flow cytometry and revealed significant reduction in epithelial 
(day 3 of culture 95%, day 7 of culture 75%) and endothelial cells (day 3 of culture 90%, day 
7 of culture 97%), respectively (Figure 24).   
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As a direct consequence, absolute cell numbers of epithelial cells and endothelial cells were 
significantly decreased at day 3 and 7 of culture. These data are in accordance with previous 
reports of growth arrest in HDAC exposed organs during development, e.g. pancreas and 
kidney (Haumaitre et al., 2008, Chen et al., 2011). 
 
Gene expression 
 
Effect of HDAC inhibition on the expression of thyroid specific genes was performed 
comparing genes belonging to transcription factors regulating thyroid development (Pax8), 
genes encoding functional proteins necessary for thyroid hormone synthesis (Nis, Tg, Tpo), 
and genes encoding adhesion molecules of epithelial cells (E-cadherin, KSP-cadherin) and 
endothelial cells (Pecam).  
 
Time course analysis revealed distinct expression patterns at day 3 and day 7 of culture: In 
analogy with results from intestine, pancreas and kidney, hyperacetylation caused a stage 
specific change in gene expression. The most dynamic expression pattern was observed for 
the gene encoding key proteins of thyroid hormone synthesis, Nis and Tpo, being reduced at 
day 3 and increased at day 7 of culture. In contrast, the only gene with unchanged expression 
pattern, thus non-responsive to HDAC inhibition and hyperacetylation, was Epcam. As 
HDAC inhibition is not only acting on promoters of genes encoding differentiation markers 
but also on promoters of transcription factors and transcriptional repressors, the gene 
expression pattern of functional genes is a result of this complex interplay between stage 
specific expression of regulators, and their sensitivity to HDAC inhibition. Such effects were 
also observed in other developing organs treated with HDAC inhibition (Tou et al., 2005; 
Haumaitre et al., 2008; Chen et al., 2011). 
 
In summary, these results reveal important changes in gene expression after HDAC inhibition 
dependent on stage of analysis, gene function, and sensitivity to HDAC inhibition. However, 
a more specific approach such as ChIP-Seq is needed to understand which genes are directly 
regulated by HDACs or acetylation, and which genes are not direct targets of HDACs. These 
experiments were not possible until 1) flow cytometry protocol for cell sorting of TFCs was 
established and 2) before low cell number ChIP-Seq became technically feasible. Now such 
experiments are underway. 
 
Summarizing the effects of HDAC inhibition and disordered histone acetylation on thyroid 
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development, we observed profoundly disordered thyroid development at all key steps of 
terminal differentiation: First, follicle formation was blocked, reducing the functional 
endocrine epithelial surface of the developing organ. Secondly, angiogenesis was strongly 
reduced, thus reducing the blood flow in the endocrine organ to secrete synthesized 
hormones. Finally, endocrine cell mass was significantly reduced, ultimately causing 
endocrine insufficiency, thus hypothyroidism.  
 
In conclusion, HDAC inhibition during terminal differentiation of the thyroid caused 
hypoplastic and dysgenetic thyroid, reminiscent of thyroid dysgenesis in patients with 
congenital hypothyroidism. As hypothesized initially, these results suggest, that disordered 
HDAC function or histone acetylation could be a new molecular mechanism for TD (Figure 
29).  
 
Figure 29. Disturbed epigenetic regulation could be a new molecular mechanism for thyroid dysgenesis in 
patients with thyroid hypoplasia and pretracheal thyroid without function. 
 
This hypothesis is further supported by very recent data from kidney development. After 
having established the critical role of general HDAC activity for kidney development, Chen et 
al showed that HDAC1 and HDAC2 deletion caused renal dysgenesis / hypoplasia. Further, 
the authors provided insight into the molecular mechanism of hypoplasia, in as revealing a 
regulatory role of HDAC1 and HDAC2 of the Wnt and p53 pathways (Chen et al 2011, 
2015).  
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6. CONCLUSIONS AND PERSPECTIVES 
 
This work focused on two main aims and projects: 
 
Project 1: First, we aimed to establish a flow cytometry protocol to identify and quantify the 
various cell populations in the developing and adult murine thyroid. 
Project 2: Second, we aimed to analyze the role of HDACs and of histone acetylation for the 
regulation of thyroid development. 
 
Project 1: A new tool for thyroid research: Flow cytometry of the thyroid gland 
 
My data provides for the first time in the field of thyroid development a new tool for the 
detection of individual cell populations, and quantification of their proliferation, apoptosis, 
and epigenetic changes by flow cytometry. In summary, 1) we present a detailed gating 
strategy to characterize 7 cell populations in the embryonic and adult thyroid gland, 2) we 
provide a detailed analysis of the cell population changes and proliferation in individual cell 
types in embryonic and differentiated mouse thyroid in vivo, and 3) we reveal a yet unknown 
and uncharacterized cell population present in embryonic and adult thyroids at a frequency 
between 5-20%. We believe that our approach will provide a useful new tool for cell function 
analysis in murine thyroid disease models. 
 
As a direct consequence of our study, the following aspects need to be studied more in detail: 
First, as shown in the submitted manuscript, a major change in frequencies of cell populations 
occurs between E17.5 and 8 weeks old adult thyroid tissues. Thus, in a follow-up study, later 
embryonic and postnatal stages will be analyzed in the same way to provide a complete 
picture of in vivo cell growth dynamics from E13.5 to adult stage. 
Second, the identified unknown cell population needs to be investigated to shed light on its 
origin, and function within the thyroid gland. Transcriptome analysis of sorted cells will 
provide a first approach to characterize the nature of this cell population. 
 
Project 2: A new concept: Epigenetic regulation of thyroid development 
 
The gathered data provide for the first time clear arguments for epigenetic regulation of 
thyroid development and a possible new mechanism for TD. 
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In summary, 1) we observed developmentally regulated dynamic changes of HDAC activity, 
HDAC expression and histone acetylation in different cell types during thyroid development 
in vivo, 2) we developed a new protocol by which we quantified the effect of HDAC 
inhibition on acetylation and tri- methylation at the bivalent histone tail residue H3K9 
(epigenetic switch), and 3) we revealed profoundly disordered thyroid development after 
HDAC inhibition compatible with all aspects of TD in patients with CH: reduced follicle 
formation, decreased endocrine cell mass, and disturbed angiogenesis.  
 
Based on this first set of experiments, the following aspects need to be analyzed in more 
depth to further extend our knowledge on the role of HDACs and histone acetylation for 
thyroid development. Some of the proposed experiments are underway: 
First, to confirm the concept, the results need to be replicated by new and more specific 
pharmacological HDAC inhibitors, e.g. selective HDAC1 blockers, which can be validated in 
conditional knockout mouse models of specific HDACs to provide in vivo proof.  
Second, we applied HDAC inhibition during a long period (3 or 7 days). It remains open, 
whether and at what critical time windows short-term HDAC inhibition can also result in 
disordered thyroid development in our model.  
Third, as our experimental HDAC inhibition was applied only from E13.5 on in our model, 
our results do not provide insights into the role of HDACs and histone acetylation at the early 
stages of thyroid development. Thus, the role of HDACs and histone acetylation remains to be 
characterized in non-lineage committed endodermal stem cells, and TFC precursors between 
E8.5-E13.5. Such experiments might give an answer to whether more severe forms of TD 
(agenesis or ectopy) might be caused by disrupted histone acetylation. 
Fourth, our study provides a detailed analysis of effects of HDAC inhibition but no insights 
into target genes and pathways regulated by HDACs and histone acetylation. ChIP-Seq 
experiments with HDAC2 and H3K9ac in vivo at E13.5, E15.5, and E17.5 are underway to 
provide a complete picture of the complex epigenetic regulatory network.  
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